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KID-KC: KID syndrome patient-derived keratinocytes 
control-KC: Healthy donor-derived keratinocytes 
AS-siRNA: Allele-specific small interference RNA
SLDT: Scrape-loading dye transfer 
RNA-Seq: RNA sequencing
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Page 3 of 109
4
ABSTRACT
Keratitis-ichthyosis-deafness (KID) syndrome is a severe, untreatable condition characterized by 
ocular, auditory and cutaneous abnormalities, with major complications of infection and skin 
cancer. 86% of cases are caused by a heterozygous missense mutation (c.148G>A, p.D50N) in the 
GJB2 gene, encoding gap junction protein connexin 26 (Cx26), which alters gating properties of 
Cx26 channels in a dominant manner. We hypothesized that a mutant-allele-specific siRNA (AS-
siRNA) could rescue the cellular phenotype in patient keratinocytes. A KID syndrome cell line 
(KID-KC) was established from primary patient keratinocytes with a heterozygous p.D50N 
mutation. This displayed impaired gap junction communication and hyperactive hemichannels, 
confirmed by dye transfer, patch clamp and neurobiotin uptake assays. A human-murine chimeric 
skin graft model constructed with KID-KC mimicked patient skin in vivo, further confirming the 
validity of these cells as a model. In vitro treatment with AS-siRNA led to robust inhibition of the 
mutant GJB2 allele without altering expression of the wildtype. This corrected both gap junction 
and hemichannel activity. Notably, AS-siRNA treatment caused only low-level off-target effects 
in KID-KC, as detected by genome-wide RNA sequencing. Our data provide an important proof-
of-concept and model system for the potential use of AS-siRNA in treating KID syndrome, and 
other dominant genetic conditions.
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INTRODUCTION 
Keratitis-Ichthyosis-Deafness syndrome (KID syndrome, [MIM 148210]) is a rare, autosomal-
dominant condition characterized by ocular and auditory impairment and hyperkeratotic skin 
lesions (Burns, 1915). Ocular involvement includes photophobia and neovascularization, 
progressively reducing visual acuity (Caceres-Rios et al., 1996), and auditory impairment features 
sensorineural hearing loss (Patel et al., 2015). Skin involvement consists of erythrokeratodermic 
or verrucous plaques, and palmoplantar keratoderma with alopecia and/or onychodystrophy 
(Caceres-Rios et al., 1996, Coggshall et al., 2013). Moreover, KID syndrome is frequently 
complicated with chronic, opportunistic cutaneous infection, resulting in failure to thrive and, in 
severe cases, septicemia (Coggshall et al., 2013). Patients are at increased risk of developing skin 
malignancies, particularly squamous cell carcinoma (Coggshall et al., 2013). These complications 
can have a significant impact on life expectancy. Current cutaneous treatment is limited to 
symptomatic management, including retinoids to attempt to improve the skin barrier, antifungal 
and antibacterial agents for infection control (Coggshall et al., 2013). There is an unmet need for 
targeted treatment of this condition. 
The cause of KID syndrome was identified as heterozygous missense mutations in the GJB2 gene 
(van Steensel et al., 2002, Richard et al., 2002), which encodes a transmembrane, gap junction (GJ) 
channel-forming protein, connexin 26 (Cx26). GJs are clustered intercellular structures found in 
virtually all contacting cell types, enabling direct cell-cell communication via the exchange of ions, 
nutrients and signaling molecules with a molecular weight < 1 kDa (Levit et al., 2015, Elfgang et 
al., 1995). Connexin proteins, the constituents of GJs, can oligomerize to form hexameric structure 
known as connexons. On the plasma membrane, connexons can either function alone as 
hemichannels, or ‘dock’ with a compatible connexon from the adjacent cell membrane to form a 
Page 5 of 109
6
GJ (Laird, 2006). Undocked hemichannels serve as a conduit between the cytoplasm and the 
extracellular space of the cell, while GJs couple the cytoplasm of adjacent cells electrically and 
biochemically (Garcia et al., 2016). 
To date, twelve missense GJB2 mutations have been reported in KID syndrome, among which the 
mutation c.148G>A, resulting in the substitution of aspartic acid for asparagine at codon 50 
(p.D50N), is by far the most common mutation, accounting for 86% of cases in the largest 
European cohort (Mazereeuw-Hautier et al., 2007). At least 10 out of the 12 identified mutations, 
including p.D50N, have been associated with aberrant hemichannel behavior (Lee et al., 2009, 
Garcia et al., 2016, Donnelly et al., 2012, Mese et al., 2011), presented as elevated membrane 
currents (Lee et al., 2009), enhanced permeability to small-molecule tracers (Mese et al., 2011), 
and/or enhanced ATP release in response to a specific stimuli (Garcia et al., 2016, Donnelly et al., 
2012). Therefore, hemichannels have been considered a potential therapeutic target when 
developing new KID syndrome treatment (Levit et al., 2015, Xu et al., 2017). Recent work has 
shown that mefloquine, an FDA-approved anti-malarial drug, potently suppresses aberrant 
hemichannels in primary keratinocytes from a transgenic mouse model with heterozygous p.G45E 
mutation in GJB2 (Levit et al., 2015). Very recently, the monoclonal antibody abEC1.1 was 
developed, which specifically suppressed hemichannels formed by Cx26-wildtype (WT), p.G45E 
or p.D50N mutants (Xu et al., 2017). However, it is unclear whether those strategies can 
discriminate mutant GJB2 allele from the WT. This concern is particularly important given the 
context that most KID syndrome mutants exert dominant effects on co-expressed WT connexins 
(Di et al., 2005, Garcia et al., 2015). In the last decade, allele-specific small interference RNA (AS-
siRNA) technology has shown strong therapeutic potential in treatment of dominant genetic 
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disorders and brought clinical benefits to a patient with pachyonychia congenita (Trochet et al., 
2015). 
We present a specific and effective AS-siRNA against the GJB2 c.148G>A (p.D50N) mutation, 
which successfully rescues the abnormal cellular phenotype in patient-derived keratinocytes. Our 
approach could potentially be a novel future therapy for this debilitating and life-limiting condition. 
RESULTS
Patient-derived keratinocytes with heterozygous c.148G>A (p.D50N) mutation had aberrant 
gap junction and hemichannel behavior and caused hyperkeratotic skin morphology
Previous studies on mutant GJB2 expression, distribution and function have largely relied on 
ectopic expression of homozygous GJB2 mutations in Xenopus oocytes (Lopez et al., 2013) and 
HeLa cells (Press et al., 2017b). These models, however, do not accurately represent the genetic 
state in KID syndrome patients who are heterozygotes for GJB2 mutations, and therefore have 
limitations when used in preclinical evaluation for new therapeutic strategies. To overcome this, 
primary keratinocytes isolated from a fresh skin biopsy of the KID syndrome patient heterozygous 
for c.148G>A (p.D50N) mutation in GJB2 were immortalized using the lentiviral vector encoding 
HPV type 16 E6/E7 cDNA. 
The mutation GJB2 c.148G>A was confirmed in the immortalized cells (KID-KCs) (Figure 1a). 
Keratinocytes obtained from a healthy donor and immortalized with the same protocol were used 
as a control (control-KCs). Both immortalized cell lines showed polygonal morphology with 
various sizes in early passages but were more uniformly shaped in later passages (Figure 1b). The 
cell morphology and genotype were monitored over a propagation period up to 45 passages. There 
was no apparent change in morphology and the mutation in KID-KCs was expressed stably. The 
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expression of endogenous GJB2 mRNA in KID-KCs and control-KCs was examined by 
quantitative reverse transcriptase-PCR (qRT-PCR) using specific primers for total GJB2. A 
reduction of 44% in total GJB2 mRNA in KID-KCs was seen compared to that in control-KCs (n 
= 4, p = 0.24) (Figure 1c). The PCR amplicon of KID-KCs was sequenced, and the chromatogram 
exhibited a 1:1 ratio for WT : mutant allele peaks at c.148 locus (Figure 1a), suggesting similar 
mRNA expression levels for both WT and mutant alleles in KID-KCs. 
The expression of the Cx26 protein was also examined by immunoblotting. Several anti-Cx26 
antibodies have been used in immunoblotting previously (Yum et al., 2007, Press et al., 2017a), 
but the majority was used to detect Cx26 in rodent cells or tissues or in HeLa cells ectopically 
expressing Cx26, and only few were able to detect endogenous Cx26 in cultured human 
keratinocytes. This is possibly due to low endogenous Cx26 level or a lack of anti-Cx26 antibodies 
with sufficient affinity/specificity. We tested six antibodies and found that the pair of a rabbit 
polyclonal antibody (Thermo Fisher Scientific, 13-8100) and a mouse monoclonal antibody 
(Merck Millipore, MABT198) gave a clear band at 26 kDa when used for immunoprecipitation 
experiments (Figure 1d). Immunoprecipitation using these pair of antibodies showed a reduction 
in Cx26 protein expression in KID-KCs compared to control-KCs, which was consistent with the 
qRT-PCR results. 
The distribution of Cx26 in the cells was determined using immunostaining. In control-KCs, 
punctate or plaque-like Cx26 staining was observed at cell-cell contact sites (Figure 1e), which 
were indicated by membranous staining of E-cadherin, suggesting that WT Cx26 was able to traffic 
to the plasma membrane and formed GJ plaques. By contrast, Cx26 in KID-KCs failed to 
accumulate at membrane regions but showed a primarily discrete punctate staining pattern in the 
cytoplasm (Figure 1e). Although a small portion of GJ plaques overlaid with E-cadherin at the 
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plasma membrane, they were smaller in size compared to those observed in control-KCs. 
Interestingly, the immunostaining pattern of the patient skin did not show striking reduction or mis-
localization of Cx26 expression (Figure 1f). This could be, in part, explained by the in vitro culture 
condition which rendered keratinocytes more proliferative and less differentiative, given that Cx26 
is predominantly expressed in differentiated keratinocytes (Churko and Laird, 2013, Martin et al., 
2014).
The function of GJ intercellular communication in KID-KCs was assessed by scrape-loading dye 
transfer (SLDT) using the neurobiotin tracer and compared to control-KCs. Neurobiotin diffused 
extensively from initially scrape-loaded cells to neighboring cells in control-KCs (Figure 2a). In 
contrast, the diffusion of neurobiotin in KID-KCs reduced markedly and was almost confined to 
the first line of the scrape-wounded cells. Quantification of the images revealed a reduction of 58% 
in diffusion area in KID-KCs, compared to that in control-KCs (n = 3 each, p < 0.01), suggesting 
that the GJ channels formed in KID-KCs were defective (Figure 2b). 
Next, the activity of hemichannels in KID-KCs was measured using whole-cell patch clamp and 
neurobiotin uptake assay. Moderate membrane currents were recorded from control-KCs at both 
depolarizing and hyperpolarizing membrane voltages, whereas large currents were elicited from 
KID-KCs at all tested membrane voltages, more prominently at depolarizing voltages between +30 
mV and +110 mV (Figure 2c). The maximum current density recorded from KID-KCs was 80% 
greater than that in control-KCs (9.0 ± 1.3 pA/pF, n = 21 cells vs. 5.0 ± 0.6 pA/pF, n = 14 cells, 
measured at +110 mV, p < 0.05) (Figure 2d). Consistent with the patch clamp results, KID-KCs 
showed a marked increase in uptake of neurobiotin tracer compared to control-KCs (n = 29 and 34 
cells, respectively, p < 0.001) (Figure 2e). These results suggested enhanced membrane 
conductivity and neurobiotin permeability in KID-KCs, indicating hyperactive hemichannel 
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behavior conferred by the mutation. Our in vitro findings indicated that, despite expressing Cx26 
at a relatively low level in culture, the KID-KCs displayed an aberrant cellular phenotype that has 
been reported previously in other KID syndrome disease models (Arita et al., 2006, Lee et al., 2009, 
Garcia et al., 2016). 
To confirm that the immortalized KID-KCs remained capable of proliferation and differentiation, 
i.e. characteristics of primary keratinocytes in vivo, these cells were tested in a human-murine 
chimeric skin graft model (Di et al., 2011). Histological examination of the skin graft regenerated 
from immortalized KID-KCs showed similar features seen in the KID syndrome patient skin, 
including hyperkeratosis and spongiosis (Figure 3). Collectively, the immortalized KID-KCs are 
a suitable model for evaluating therapeutic efficacy of AS-siRNA for KID syndrome.
AS-siRNA selectively inhibited the c.148G>A mutation in KID-KCs
Nineteen candidate AS-siRNAs with a targeting sequence complementary to the c.148G>A 
mutation (S1−S19) were screened at a concentration of 50 nM in Hela cell lines stably expressing 
WT or mutant GJB2 fused with the GFP reporter gene. Both cell lines were transfected with each 
of 19 AS-siRNAs, followed by flow cytometry analysis for reduction of GFP intensity 
(Supplementary Figure S1b). The knockdown efficiency of S7 and S10 in cells expressing the 
mutant GJB2-GFP was approximately 50%. Since S7 inhibited mutant GJB2 specifically and 
reproducibly from three independent screening experiments (Supplementary Figure S2), this 
siRNA was selected for further study. 
The allele-specific action of S7 at 50 nM was tested in the KID-KCs harboring the heterozygous 
mutation. KID-KCs and control-KCs were treated with S7 and the mRNA expression of GJB2 in 
treated cells was examined 24 hrs post-treatment by qRT-PCR. The treatment resulted in a 
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significant decrease of 63% in total GJB2 mRNA in KID-KCs compared to untreated cells (n = 3, 
p = 0.0065), but the decrease was not detected in control-KCs with the same treatment (n = 3, p = 
0.84) (Figure 4a). Further investigation using allele-specific primers showed no difference in 
mRNA expression of the WT allele between untreated and S7-treated cells (n = 3, p = 0.51 for 
KID-KCs and p = 0.60 for control-KCs), whereas mRNA expression of the mutant allele in KID-
KCs was significantly inhibited by 43% following S7 treatment (n = 3, p = 0.0065). At protein 
level, Cx26 expression showed an average decrease of 56% (range 52−64%, n = 3) in total 
endogenous Cx26 expression in KID-KCs following S7 treatment, compared to those treated with 
an irrelevant siRNA, si-cont (Figure 4b-c). This change was not detected in S7-treated control-
KCs, which showed a slight increase in Cx26 expression (range 5−16%, n = 3). All these results 
indicated that S7 had strong selectivity for the mutant GJB2 c.148G>A allele over the WT allele 
in the patient keratinocytes, and it had little effect on the normal keratinocytes where only the WT 
allele was present.  
AS-siRNA treatment reversed aberrant gap junction and hemichannel functions in KID-KCs
KID-KCs treated with S7 or si-cont at 50 nM were further analyzed for GJ intercellular 
communication and hemichannel activity. GJ-mediated intercellular diffusion of neurobiotin tracer 
was analyzed 24 hrs post-treatment using the SLDT assay. The results showed a 24% increase in 
neurobiotin diffusion in KID-KCs treated with S7 compared to those treated with si-cont (n = 34 
and 37 images, respectively, p < 0.01) (Figure 5b, d), whereas no significant difference in 
neurobiotin transfer was observed in control-KCs treated with either S7 or si-cont (n = 30 and 35 
images, respectively, p > 0.05) (Figure 5a, c). The hemichannel activity in the treated cells was 
assessed by whole-cell patch clamp. The results showed a decrease of 35% in membrane current 
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density in KID-KCs treated with S7, compared to those treated with si-cont (9.02 ± 1.16 pA/pF, n 
= 20 cells vs. 5.86 ± 0.43 pA/pF, n = 22 cells, measured at +110 mV, p < 0.05), while no statistical 
differences were found in control-KCs following S7 or si-cont treatment (n =10 cells each group, 
p > 0.05) (Figure 5f-h). Notably, the current density level in S7-treated KID-KCs was comparable 
to that in control-KCs. The activity of hemichannels was further examined by neurobiotin uptake 
assay, which showed a significant decrease in neurobiotin uptake in KID-KCs after S7 treatment 
(n = 21 and 27 images, p < 0.001), in line with the patch clamp results (Figure 5i-j). 
These findings suggested functional recovery following the inhibition of mutant GJB2 allele by 
S7, namely improvement of the defective GJ-mediated cell coupling and reversal of the aberrant 
non-junctional hemichannel behavior, including electrical conduction and permeability. 
Low-level off-target effects of AS-siRNA, S7
Despite promising efficacy data obtained from S7, a general concern in preclinical AS-siRNA 
studies is off-target effects that may cause unintended alteration in unrelated gene expression 
(Trochet et al., 2018). To explore comprehensively the specificity of S7, RNA-Seq was carried out 
S7-treated or non-treated KID-KCs. 26485 genes from the libraries were mapped to the reference 
human genome (with 15,802 null- or low-expressed genes), among which only 6 genes were found 
to be differentially expressed in S7-treated KID-KCs compared to the non-treated cells (range of 
fold change: 2.01−2.32), indicating that S7 resulted in mild global effects on the KID-KC 
transcriptome. To validate the results, the top 5 upregulated (MMP1, MMP10, MMP9, ANGPTL4, 
CXCL5) and downregulated genes (GLB1L2, NSA2, AFAP1L1, GPR137, TMEM109) were further 
analyzed by qRT-PCR (Table 1). Control-KCs with or without S7 treatment were run in parallel 
as additional controls. The results confirmed the upregulation of the MMPs and the downregulation 
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of GPR137 in KID-KCs with comparable levels of fold change (Supplementary Figure S4); 
however, the MMPs were also found upregulated in S7-treated control-KCs. 
A common cause of siRNA-mediated gene alteration is sequence matching between the seed region 
of siRNA and the target mRNA (Yilmazel et al., 2014, Jackson and Linsley, 2010). To investigate 
whether this was an underlying mechanism for the differential expression of the above genes, we 
employed the online tool, genome-wide enrichment of seed sequences (GESS), to analyze the 
sequence of S7. A total of 180 genes were found to have sequence match(es) with S7 
(Supplementary Table S2), among which only GPR137 was found, with its 3’-untranslated region 
and coding sequence complementary to the seed region of either of the S7 strands. This implied 
that downregulation of GPR137 may have resulted from seed region-dependent off-target effects. 
The mechanism of alteration of the other genes remains to be clarified.
DISCUSSION 
We study AS-siRNA using KID-KC, an immortalized, patient-derived keratinocyte cell line which 
harbors a heterozygous c.148G>A mutation, representing the genetic state in KID syndrome 
patients. Although use of primary keratinocytes from patient skin biopsy would have been ideal 
for this study, these cells have a limited lifespan which restricts us from performing multiple 
experiments. To bypass the restrictions, we used immortalized patient keratinocytes due to their 
indefinite lifespan and capability of proliferation and differentiation, i.e. features of primary 
keratinocytes (Choi et al., 2017). This was further confirmed in our in vivo skin graft experiments, 
where regenerated skin grafts from immortalized KID-KCs recapitulated the epidermal 
architecture of the KID syndrome patient skin.
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Our immunostaining found lower Cx26 expression level in cultured immortalized cells compared 
to that in skin tissues. This is not surprising, as monolayer culture contains a dominating proportion 
of proliferating keratinocytes with low-level Cx26 expression (Martin et al., 2014). Despite the 
lower expression, we were able to show aberrant hemichannel and GJ behavior in KID-KCs, which 
is in line with data generated from previous in vitro models such as Xenopus oocytes (Lee et al., 
2009, Sanchez et al., 2013), HeLa cells (Di et al., 2005) and corneal epithelial cells (Shurman et 
al., 2005) ectopically expressing the c.148G>A mutant. This suggested that the reduced Cx26 
expression in vitro is unlikely to influence the interpretation of our results. Collectively, the 
immortalized, patient-derived model, which recapitulates the genetics, cellular and histological 
phenotypes of the condition, has significant advantages over the previous models and hence can 
serve as a good preclinical model for translational development of new therapeutic approaches.
The action of previously reported approaches to inhibit connexins, including monoclonal 
antibodies (Xu et al., 2017) and synthetic peptide mimetics (Becker et al., 2012), is mediated by 
either altering the biophysical property of target connexin channels or modulating interaction 
between target connexins and their binding partners. In contrast to those approaches, AS-siRNA 
silences target gene expression by degrading mRNA based on perfect sequence matching, thereby 
blocking the translation of target protein (Jackson and Linsley, 2010). As AS-siRNA is able to 
discriminate mutant and WT mRNA sequences differing by even a single base, we harness this 
technology to develop a targeted therapy for KID syndrome. Our results have confirmed that the 
lead AS-siRNA, S7, targeted to the mutant GJB2 allele in a potent and specific manner while 
maintaining expression of the WT allele and its protein function, providing strong basis for future 
translation of the AS-siRNA. 
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In human keratinocytes, Cx26 forms heteromeric and heterotypic channels with other compatible 
types of connexins (Di et al., 2001). These heterogenous channels have biophysical properties 
differing from their homogenous counterparts, providing dynamic regulation in response to 
different stimuli. Recent studies proposed that aberrant interaction with Cx43 is an emerging 
mechanism by which certain Cx26 mutants can cause diseases through heteromeric channels 
(Garcia et al., 2015, Shuja et al., 2016). We performed double immunofluorescence staining in our 
patient skin tissues and cultured KID-KCs, and the results did not show clear colocalization 
between Cx26 and Cx43 (data not shown). As this is our preliminary data, further investigation is 
required in the future. 
The low endogenous expression of Cx26 in human keratinocytes (Richard et al., 2002, Di et al., 
2001) posted a challenge in our initial attempts of immunoblotting to detect Cx26, which showed 
multiple bands. Issues regarding the presence of multiple bands were also reported by others 
(Gassmann et al., 2009), and were considered to result from oligomers and protein aggregates of 
Cx26. Our optimized immunoprecipitation/immunoblotting approach allowed enrichment of low-
abundant Cx26 in cultured patient keratinocytes, leading to successful quantification of siRNA-
medicated Cx26 knockdown. 
Our work provides proof-of-concept for the use of AS-siRNA in targeted therapy for KID 
syndrome. In the context of patient skin, the AS-siRNA-mediated reversal of connexin channel 
function may possibly improve the disturbed epidermal Ca2+ gradient that is contributed by 
homomeric or heteromeric channels formed by mutant Cx26 (Bosen et al., 2015), thereby leading 
to improved hyperkeratotic phenotype. Also, since enhanced hemichannel activity has been linked 
to release of inflammatory cytokines when exposing c.148G>A-expressing keratinocytes to 
peptidoglycans from an opportunistic pathogen, Staphylococcus aureus (Donnelly et al., 2012), 
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AS-siRNA is also likely to contribute towards control of skin infection and inflammation. 
Furthermore, the c.148G>A mutation has been found in the majority of KID syndrome patients. 
Thus, the mutation-targeted AS-siRNA would serve as potentially effective and safe therapeutic 
intervention for KID syndrome, the debilitating condition that has no effective specific treatment 
options at present. Although in vivo delivery of siRNA remains challenging, strategies including 
nanoparticles (Zheng et al., 2012), penetration enhancers (Hegde et al., 2014), microneedles 
(Chong et al., 2013) and electroporation (Broderick et al., 2012) have shown promise in topical 
siRNA delivery into the skin in a non- or minimally-invasive manner, causing silencing of target 
genes. We are currently optimizing a topical delivery platform and the therapeutic efficacy of the 
AS-siRNA will be tested in our in vivo human-murine chimeric skin graft model generated using 
immortalized KID-KCs. If successful, our strategy could potentially be adapted to other skin 
conditions with dominant mutations. 
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MATERIALS AND METHODS 
KID syndrome patient-derived keratinocytes 
3-mm punch biopsies from a KID syndrome patient with the heterozygous c.148G>A mutation, 
and a healthy volunteer donor, were obtained under a protocol approved by the local ethics 
committee (12/LO/1522) with informed written consent. The epidermis was isolated freshly from 
the biopsies as described previously (Di et al., 2011). The primary keratinocytes were immortalized 
by transduction with a second-generation, replication-deficient, self-inactivating HIV-1 lentiviral 
vector (Yanez-Munoz et al., 2006) constructed with human papilloma virus type 16 E6/E7 cDNA 
(Supplementary Figure S3). Immortalized cells were established following serial propagation and 
thereafter were cultured in the keratinocyte culture medium without feeder cells. 
Statistical analysis
All data were expressed as the mean ± standard error of the mean (SEM). Comparisons of data 
from qRT-PCR, patch clamp, neurobiotin uptake and SLDT experiments were made by Student’s 
t-test using GraphPad Prism v6.01 (GraphPad Software, San Diego, CA, USA). Differences with 
a p-value less than 0.05 were considered statistically significant. *p < 0.05; **p < 0.01; and ***p 
< 0.001.
Detailed methods for immunostaining, siRNA design, qRT-PCR, immunoprecipitation and 
immunoblotting, patch clamp, neurobiotin uptake, SLDT, RNA-Seq and in vivo skin graft 
experiments are described in Supplementary Materials.
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TABLES
Table 1. Top five up- and downregulated genes from the RNA-Seq experiments
Top five upregulated genes (KID-KCs, S7 vs. untreated)
Gene Protein Fold Change *p-adj
MMP1 Matrix metalloproteinase-1 2.24, up 9.50E-22
MMP10 Matrix metalloproteinase-10 2.06, up 4.19E-30
MMP9 Matrix metalloproteinase-9 1.95, up 4.90E-65
ANGPTL4 Angiopoietin-like 4 1.93, up 3.57E-28
CXCL5 C-X-C motif chemokine 5 1.74, up 6.26E-45
Top five downregulated genes (KID-KCs, S7 vs. untreated)
Gene Protein Fold Change *p-adj
GLB1L2 Galactosidase Beta 1 Like 2 2.31, down 2.17E-14
NSA2 Ribosome biogenesis homolog 2.16, down 1.99E-68
AFAP1L1 Actin filament-associated protein 1-like 1 2.01, down 1.99E-27
GPR137 G protein-coupled receptor 137 2.00, down 3.96E-09
TMEM109 Transmembrane Protein 109 1.94, down 3.92E-47
*p-adj, adjusted p-value for multiple statistical testing (Benjamini-Hochberg method) 
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FIGURE LEGENDS
Figure 1. Genotype, morphology, GJB2 expression and subcellular localization in 
keratinocytes 
cDNA sequences of GJB2 from the KID syndrome patient and healthy donor are shown in (a). The 
morphology of keratinocytes from healthy donor and KID patient at early passages (P1 or P5) and 
late passages (P35 or P45) is shown in (b). The mRNA expression of total GJB2, the wildtype 
(WT) allele and the mutant allele in healthy donor and KID patient keratinocytes determined by 
qRT-PCR are shown in (c). The total Cx26 protein (asterisk, at 26 kDa) expression was examined 
by immunoprecipitation and immunoblotting (d), which shows decreased Cx26 expression in 
patient cells. The expression of Cx26 detected by immunofluorescence staining is shown in (e), 
where gap junction plaques can be found at cell-cell junctions in normal keratinocyte (arrows), 
whereas Cx26 in KID patient keratinocytes was localized discretely in the cytoplasm (arrowheads). 
E-cadherin (E-Cad) was stained in green color. Cx26 expression in the skin is shown in (f), where 
punctate staining of Cx26 was observed (arrows). The dotted lines show dermal-epidermal junction. 
Bar = 100 μm (b) and 40 μm (e, f). KID: KID patient-derived keratinocytes; Cont: keratinocytes 
derived from the healthy donor; N.S: not significant; ***p < 0.001.
Figure 2. Abnormal gap junction and hemichannel behavior in KID-KCs
The gap junction intercellular communication in KID-KCs (KID) or control-KCs (Cont) was 
examined by the SLDT assay, and the hemichannel activity was examined by whole-cell patch 
clamp and neurobiotin uptake. Representative images of SLDT in the keratinocytes using 
neurobiotin tracer (red) is shown in (a). Data analysis (b) shows that KID-KCs had impaired ability 
to transfer neurobiotin to adjacent cells. Representative patch clamp records from single 
Page 25 of 109
26
keratinocytes in response to the voltage step protocol from -110 mV to +110 mV in 20 mV 
increments are shown in (c). The plot of current density against membrane voltage reveals 
aberrantly enhanced hemichannel activity in KID-KCs (d). Representative images of neurobiotin 
uptake (NB, red) are shown (e), with the nuclei stained with DAPI (blue). Data analysis shows 
increased uptake of NB in KID-KCs (f). All data are presented as the mean ± SEM. *p < 0.05; 
***p < 0.001. Bar = 200 μm. 
Figure 3. Epidermal morphology of grafted skin in human-murine chimeric skin graft model 
Primary fibroblasts and immortalized keratinocytes derived from the KID syndrome patient 
harboring heterozygous GJB2 c.148G>A mutation or a healthy donor were used to generate bio-
engineered skin sheets, which were grafted onto NOD-severe combined immunodeficiency mice 
(NSG mice). Eight weeks post-grafting, regenerated skin grafts were harvested. Macroscopic 
examination showed fine, dry scales in the graft generated from patient cells (d) compared to that 
generated from control cells (a). Histological examination showed hyperkeratosis and spongiosis 
in the patient skin graft (f), resembling that seen in the patient skin (c). The skin architecture of the 
control skin graft (e) was also similar to healthy donor skin (b). Bar = 100 µM.
Figure 4. Allele-specific GJB2 knockdown by S7
The mRNA expression of total GJB2, wildtype (WT) and the mutant (MUT) GJB2 alleles in 
control-KCs (Control) and KID-KC (KID) treated with AS-siRNA S7 was examined by qRT-PCR 
and compared to untreated cells (UT) (a). Total Cx26 protein expression in S7-treated cells from 
three independent immunoprecipitation(IP)/immunoblotting(IB) experiments (b). The expression 
was quantified using densitometry (c). β-actin was used as a loading control and HeLa cells were 
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used as a negative control. A reduction in total Cx26 expression was detected in KID-KCs after S7 
treatment, but such a change was not detected in control-KCs. N.S, not significant; **p < 0.01
Figure 5. S7 treatment corrected abnormal gap junction and hemichannel functions in KID-
KCs 
SLDT was performed in siRNA-treated KID-KCs (KID) and control-KCs (Cont) to assess GJ 
activity (a, b). The analysis of neurobiotin transfer (red) is shown (c, d). Each dot in panels c and 
d represents the average neurobiotin transfer from a single image. Three independent experiments 
were carried out and at least ten images were analyzed from each experiment. Restoration of GJ 
activity was detected in KID-KCs following S7 treatment. Whole-cell patch clamp (e-h) and 
neurobiotin uptake (i, j) were carried out to examine hemichannel activity. Records of currents 
from single cells under the voltage step protocol (e) are shown (f, g). The plot of current density 
against membrane voltage shows correction of hyperactive hemichannels in KID-KCs after S7 
treatment (h). Representative neurobiotin (NB, red) uptake images are shown in (i). The nuclei 
were stained with DAPI (blue). Data analysis shows reversal of aberrantly enhanced NB uptake in 
KID-KCs (j). Data are presented as the mean ± SEM. N.S, not significant; *p < 0.05; **p < 0.01; 
***p < 0.001. Bar = 200 μm. 
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Frozen tissue sections (6 μm) or paraformaldehyde-fixed cultured cells were incubated in PBS 
containing 3% fetal bovine serum and 0.3% Triton X-100 for 20 min at room temperature, and then 
incubated overnight at 4°C with a monoclonal Cx26 antibody (1:50; Thermo Fisher Scientific; Cat. 
#13-8100). Following several rinses with PBS, samples were incubated with a biotinylated 
secondary antibody (1:100; Vector Laboratories, Peterborough, UK) for 1 hr prior to visualization 
using an Alexa-Fluor 488- or 568-conjugated streptavidin (1:500; Invitrogen, Paisley, UK). 
Samples were counterstained with 5 µg/ml 4,6-diamino-2-phenylindole (DAPI, Vector 
Laboratories, Peterborough, UK), mounted using 10% Mowiol (Calbiochem, Nottingham, UK), 
and imaged using a Zeiss LSM 510 laser confocal microscope (Zeiss, Oberkochen, Germany). 
Images were recorded under the same settings (laser power, digital offset and gain) from three to 
seven continuous, non-overlapping fields on each slide, and analyzed using ImageJ v1.51n (NIH, 
Bethesda, MD, USA). 
siRNAs
Nineteen candidate AS-siRNAs (S1−S19) were designed and synthesized (Sigma, Dorset, UK). In 
siRNA screening experiments, the Silencer™ siRNA against GFP (Thermo Fisher Scientific, 
Paisley, UK) was used as a positive control (i.e. indicator of transfection and knockdown efficiency) 
and the siRNA against human HAS2 was used as a negative control (si-cont, Sigma, Dorset, UK). 
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The sequences of si-cont are: sense 5’-AUAUCGUCAUGGUCUUCAU[dT][dT]-3’, and antisense 
5’-AUGAAGACCAUGACGAUAU [dT][dT]-3’.  
Screening of AS-siRNAs
A fluorescence-based screening system was generated using HeLa cells stably expressing ectopic 
GJB2-WT or GJB2-c.148G>A which was fused to GFP cDNA at the 3’-terminus, driven by the 
cytomegalovirus promoter (CMV) (Supplementary Figure S4). We used the HIV-1 derived, self-
inactivating lentiviral vector pLNT-SFFV-MCS, with the WT or mutant CMV-GJB2-GFP cDNA 
sequence subcloned in. Lentiviruses were packaged by co-transfecting HEK-293T cells with the 
WT or mutant lentiviral vector, together with a plasmid encoding the vesicular stomatitis virus 
envelope and a packaging plasmid pCMV8.74 coding for lentiviral gag, pol and accessory proteins, 
tat and rev. Infectious viruses were harvested 72 hrs post-transfection, filtered through a 0.45-μm 
pore cellulose acetate filter, and then ultra-centrifuged at 23,000 × g for 2 hrs. Concentrated viruses 
were resuspended in the Opti-MEM® medium and the lentivirus stocks were kept at -80°C until 
use. The viral titres assessed by GFP expression using flow cytometry were 8.8×107 infectious unit 
(IU)/ml for WT viruses and 4.9×106 IU/ml for mutant viruses. HeLa cells were transduced with 
either WT or mutant lentiviruses and, upon confluence being reached, fluorescence-activated cell 
sorting was carried out to obtain single GFP+ cells using a Moflo XDP flow cytometer (Beckman 
Coulter, Luton, UK). These single cells were cultured until clonal expansion was observed. 
GFP+ clonal HeLa cells were seeded in a 24-well plate and, upon reaching a 70% confluence, were 
transiently transfected with each AS-siRNA at a concentration of 50 nM, using Lipofectamine™ 
RNAiMAX (Thermo Fisher Scientific, Paisley, UK). 24 hrs post-transfection, the level of GJB2-
GFP expression was assessed using flow cytometry (FACSCalibur™, BD Biosciences, Oxon, UK). 
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Briefly, a non-fixed cell suspension was prepared in PBS containing 2% fetal bovine serum. 10,000 
cells from each sample were acquired using the FL1 channel with a 530-nm emission filter. Data 
were analyzed using the FlowJo software v10 (Tree Star Inc., Oregon, USA) and knockdown 
efficiency was indicated by the decrease of mean GFP intensity (I) in transfected cells, calculated 
as: [1- (I allele-specific siRNA / I control siRNA)] × 100%.
Quantitative reverse transcriptase-PCR (qRT-PCR)
Total RNA was extracted from cells using TRIzol® reagent (Thermo Fisher Scientific, Paisley, UK). 
Complementary DNAs (cDNAs) were generated using the GeneAmp® RNA PCR Core Kit 
(Applied Biosystems, Warrington, UK). qRT-PCR was carried out using iTaq™ universal SYBR 
Green Supermix (Bio-Rad, Watford, UK). All primers used (including the c.148G>A allele-specific 
primers) are listed in Supplementary Table S1. The reactions were performed in triplicate on a 
C1000™ Thermal Cycler (Bio-Rad, Watford, UK) with conditions as follows: initial denaturation 
at 95°C for 1 min, followed by 39 thermocycles of 95°C for 15 s and 60°C for 30 s. Individual 
levels were normalized to GAPDH expression. qRT-PCR data were collected and analyzed using 
CFX-3.1 (Bio-Rad, Watford, UK) and relative expression of GJB2 was calculated using the 2-ΔΔCt 
method.
Immunoprecipitation and immunoblotting
Cells were cultured in a 100-mm dish to confluence, washed twice in PBS, and lysed using an 
immunoprecipitation (IP) lysis buffer containing 10 mM Tris-HCl (pH 7.4), 150 mM NaCl, 1% 
Triton X-100, 0.5% NP-40, 1 mM EDTA, 1 mM EGTA, 1 mM PMSF supplemented with protease 
inhibitor cocktail. The lysates were incubated on ice for 15 min with occasional vortexing, and then 
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centrifuged at 12,000 × g at 4°C for 10 min. 1−1.5 mg protein from the supernatant was transferred 
to a fresh tube. 0.75 μg of a polyclonal Cx26 antibody (Thermo Fisher Scientific, Paisley, UK, Cat. 
#71-0500) was added to the lysate and incubated at 4°C for 2.5 hrs. Protein G-Sepharose beads (GE 
Healthcare, Buckinghamshire, UK) of a 50% slurry was added to the lysate and mixed overnight at 
4°C. The beads were harvested by brief centrifugation and washed in IP lysis buffer without 
detergent. The final pellet was resuspended with a sample buffer containing 125 mM Tris-HCl (pH 
6.8), 5% β-mercaptoethanol, 4% sodium dodecyl sulfate (SDS), 10% glycerol and 0.0004% 
bromophenol blue, and boiled at 95°C for 10 min with brief vortexing to dissociate antigen-
antibody complexes from the beads. Samples were briefly centrifuged, and supernatants were 
analyzed immediately by immunoblotting (IB). The supernatant samples were separately by 
standard 12% SDS-PAGE in the NuPAGE™ MES SDS running buffer (Thermo Fisher Scientific, 
Paisley, UK). Membranes were blocked in 5% skimmed milk in PBS and then probed with a 
monoclonal Cx26 antibody at 1:1000 dilution (Merck Millipore, Watford, UK, Cat. #MABT198). 
An anti-mouse HRP-conjugated secondary antibody at 1:4000 dilution (GE Healthcare, 
Buckinghamshire, UK) was used. The target protein was detected using the ECL™ Prime Western 
Blotting Detection system (Amersham, Buckinghamshire UK). Densitometric analysis was 
performed on scanned images of blots.
Patch clamp for hemichannel activity
Whole-cell patch clamp was carried out at room temperature as previously described (Levit et al., 
2015). Cells were seeded onto 12-mm glass coverslips, which were later transferred to an 
experimental chamber filled with Tyrode’s bath solution containing (in mM): NaCl 137.7, KCl 5.4, 
NaOH 2.3, MgCl2 1, glucose 10, and HEPES 5 (pH 7.4). Patch pipettes were pulled from glass 
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capillaries to a resistance of 3 6 MΩ with a horizontal puller (P-87, Sutter Instruments, Novato, ―
CA). Pipettes were filled with a solution containing (in mM): K-aspartate 120, HEPES 5, ethylene 
glycol tetraacetic acid 10, and NaATP 3 (pH 7.2). Solitary cells were measured for membrane 
capacitance (Cm) and membrane currents (Im) invoked while the membrane potential was stepped 
from -110 mV to +110 mV in 20 mV increments. Voltage and current signals were recorded using 
an Axopatch-1D patch clamp amplifier coupled to a Digidata 1322A interface (Axon Instruments, 
Foster City, CA). Data were acquired and analyzed using Clampex 9.2 and Clampfit 10.2 software 
(Axon instruments), respectively. To control for variability in size of recorded cells, membrane 
current density (Im/Cm) was used as a direct measure of hemichannel activity. Comparison was 
made between current density at individual membrane voltages.
Neurobiotin uptake assay for hemichannel activity
The method was modified from a protocol described previously (Mese et al., 2011). Cells plated at 
a low density were gently washed twice with Ca2+, Mg2+-containing Hank's balanced salt solution 
(HBSS, Thermo Fisher Scientific, Paisley, UK), and then incubated in 0.1 mg/ml neurobiotin 
(Vector Laboratories, Peterborough, UK), a non-fluorescent tracer, in divalent-free HBSS at 37°C 
for 10 min to allow uptake of neurobiotin through open hemichannels. After two washes in Ca2+, 
Mg2+-containing HBSS, cells were fixed with 4% paraformaldehyde in PBS at 4°C, permeabilized 
with 0.3% Triton X-100 (Sigma, Dorset, UK) and then stained with Alexa Fluor 568-streptavidin 
conjugate at 1:400 dilution (Thermo Fisher Scientific, Paisley, UK) at room temperature. Labelled 
samples were imaged using an Olympus IX71 inverted fluorescence microscope (Olympus, Essex, 
UK) with the same exposure time applied to all samples. Five to ten neurobiotin uptake images 
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from each group were recorded and analyzed using ImageJ v1.51n (NIH, Bethesda, MD, USA), 
and hemichannel activity was determined by the intensity of intracellular neurobiotin. 
 
SLDT assay for gap junction intercellular communication
The scrape loading dye transfer assay (SLDT) was performed as described previously with minor 
modifications (Yum et al., 2007). Confluent monolayer cell cultures (24- or 48 hrs post-seeding) 
were gently rinsed twice with Ca2+, Mg2+-containing HBSS, and then replaced with divalent-free 
HBSS containing 0.1 mg/ml neurobiotin. Multiple parallel scrape lines were made on the cultures 
using a sharp scalpel blade, followed by incubation at 37°C for 10 min. Cells were washed twice 
with Ca2+, Mg2+-containing HBSS, fixed with 4% paraformaldehyde in PBS, and stained as 
described in the neurobiotin uptake assay section. Stained samples were imaged using an Olympus 
IX71 inverted fluorescence microscope. At least six scrape-wounded images and three background 
(non-scrape-wounded) images were recorded from each group. Images were analyzed using ImageJ 
v1.51n. GJ intercellular communication was determined by the extent of dye transfer, quantified by 
the total area between the scrape line and the point at which the fluorescence level reduced to 1.5 × 
the background fluorescence level.
Bio-engineered skin and human-murine chimeric skin graft model
The methods for preparing and grafting bioengineered skin in immunodeficient mice have been 
described previously (Di et al., 2011). In brief, immortalised KID-KCs at passage 7 were seeded on 
top of a fibrin matrix populated with live primary fibroblasts (passage 3) isolated from the KID 
syndrome patient. After keratinocytes reached confluence, the bio-engineered skin constructs were 
grafted onto the dorsum of 22-week-old NOD-severe combined immunodeficiency mice (NOD scid 
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gamma [or NSG] mice, Charles River, UK). Three months post-grafting, mice were anesthetized 
and skin samples from graft area were taken post-mortem, embedded in paraffin and sectioned for 
histological examination.
RNA sequencing (RNA-Seq) and data analysis
Cultured KID-KCs treated in triplicate with AS-siRNA were subject to RNA-Seq experiments 24 
hrs post-treatment and untreated cells were used as a control. RNA was extracted using TRIzol® 
reagent (Thermo Fisher Scientific, Paisley, UK) and RNA quality was measured using an Agilent 
Bioanalyser. All samples had an RNA integrity number greater than 9.8. cDNA libraries were 
prepared using the KAPA mRNA HyperPrep Kit (KAPA Biosystems) according to manufacturers' 
instructions. The libraries were sequenced with a 43-bp paired-end run using a NextSeq 500 
instrument (Illumina, San Diego, US). The sequence reads are available at GEO accession 
GSE131709.
Data were first demultiplexed and converted to fastq files using bcl2fastq Conversion (v2.19, 
Illumina). Fastq files were then pre-processed to remove adapter contamination and poor-quality 
base calls (Q20 or below) using a 5’ to 3’ sliding window approach. The remaining read data were 
mapped to the hg38 reference genome using the gapped aligner, RNA-STAR (v2.5b). Read data 
were counted per transcript by FeatureCounts (v1.4.6p5). Normalization, modelling and differential 
expression analysis were carried out using the SARTools package (v1.3.2, BioConductor). All 
reference genomes and annotation were obtained from the Illumina iGenomes repository. 
Differentially expressed genes were determined using a threshold of p-adj < 0.05 and |log2 fold 
change| ≥ 1 (Speranza et al., 2017).
Page 39 of 109
8
Supplementary Tables
Supplementary Table S1. Primers 
Target Forward primers (5’-3’) Reverse primers (5’-3’)
Total GJB2 CTCCCGACGCAGAGCAAA GGTTGCCTCATCCCTCTCAT
GJB2 WT CTCCCGACGCAGAGCAAA GGCTGCAGGGTGTTGCAGACAATGTC
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Supplementary Table S2. List of 180 genes predicted to have seed sequence match with S7 
ABCA1 CRB2 IFT88 MED13L PLXNB1 SLC6A8
ABCC3 CREBBP IGF2R MED17 PPP4R1 SMCR7
ADAMTS7 CSPG4 IGSF9B MEGF8 PPRC1 SON
ADCK4 CTNNA1 INTS10 MST1R PRKCQ SPEN
ADCY1 CUL9 IQGAP3 MTF2 PRR14L STRBP
ADCY10 CYP2S1 KANSL2 MYO16 PRSS21 SVIL
ADH4 DAGLA KANSL3 NAT10 PRX SYNE2
AFP DMBT1 KAT5 NAV3 PSD3 SZT2
AGBL1 DSG2 KCNH4 NBEAL2 PTPRB TAF1
ANKRD28 DTNA KCNH5 NCOA1 RAB11FIP5 TAF5L
APOB DZANK1 KCNK16 NEURL4 REG1A TBCD
ARHGAP44 EDC4 KDR NLRC5 RINT1 TEK
ASH1L ERN1 KIAA0556 NLRP8 RNF17 TENM1
ATP13A1 ESPL1 KIAA1671 NOD1 RREB1 TENM4
BCAN FBXW2 KIAA1755 NOS2 RTTN TEP1
BIRC6 FCGBP KIDINS220 OCA2 RYR3 TLE2
BPIFB4 FLT1 KNTC1 OR51E1 SCN2A TLR8
C12orf55 FOCAD LAMA1 PCDH19 SCN3A TMPRSS4
C12orf63 FRAS1 LAP3 PCDHB13 SEC23A TRAK2
C16orf62 GALNT8 LIM2 PCDHB16 SEC31B TRIM60
C5 GJA10 LLGL2 PCDHGA6 SEMA4A TTC3
C6orf132 GNRHR LOC101929274 PCNXL3 SLC12A1 TUBGCP6
CACNA1B GPR112 LOC400499 PI4KA SLC26A6 UNC13A
CAND2 GPR137 LRP1B PIGV SLC30A5 URB1
CDS2 GRM3 LTBP4 PIWIL2 SLC35B1 UTRN
CNOT1 GRM8 LTN1 PKD1 SLC37A2 VPS13D
COL15A1 GSG2 LY75 PKHD1 SLC44A3 VWF
COL20A1 GTPBP2 LY75-CD302 PLCB3 SLC45A3 WNK2
COL4A2 HLCS MAGEL2 PLEKHG2 SLC4A4 WRN
COPA HLTF MAP7 PLEKHM2 SLC5A9 ZSWIM8
*Among the 180 genes, only GPR137 (underlined, bolded) was found in the top five up- or 
downregulated genes in KID-KCs treated by S7
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Supplementary Figures
Supplementary Figure S1. AS-siRNAs: design and screening 
19 AS-siRNAs (with a 19-nt targeting sequence plus a deoxythymidine dinucleotide) were designed 
and designated GJB2 c.148G>A_S1−S19 (or S1−S19 in short form). WT and mutant GJB2 
sequences are shown and aligned with the siRNAs, with c.148G>A mutation underlined (a). 
Fluorescence-based screening results of the 19 AS-siRNAs in HeLa cells expressing WT or mutant 
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GJB2-GFP fusion transgene are shown (b). The GFP siRNA (si-GFP) and the irrelevant siRNA (si-
cont) were used as positive and negative controls, respectively. The GJB2 knockdown efficiency 
of the AS-siRNAs was determined by the decrease in GFP intensity detected by flow cytometry (n 
= 3). The lead AS-siRNA, S7, inhibited the mutant GJB2 potently and specifically, but did not 
inhibit the WT GJB2. Data are normalized to the levels from cells treated with si-cont and shown 
as mean ± SEM.


















































Supplementary Figure S2. Validation of AS-siRNA screening suggested potent and mutation-
specific inhibitory activity of S7 
HeLa cells treated with 50 nM AS-siRNA (S7-S10), si-cont (cont), or si-GFP (GFP) were examined 
for Cx26-GFP protein expression using flow cytometry (a) and for total GJB2 mRNA using qRT-
PCR (b). Mutant-specific inhibition was achieved by S7 and S10 (a). These two siRNAs were 
further tested at mRNA level and non-specific inhibition of wildtype (WT) GJB2 was detected in 
cells treated with S10, but not in those treated with S7 (b). N.S, not significant; **p < 0.01; *p < 
0.001.
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. 
Supplementary Figure S3. Schematic of the LNT-CMV-GJB2-GFP lentiviral vectors 
Panel a shows the self-inactivating, HIV-1-based vector with the transgene cloned in, which 
encodes the wildtype or c.148G>A mutant GJB2 cDNA fused to GFP reporter cDNA at the 3’ 
terminus driven by the cytomegalovirus promoter (CMV). Panel b shows the packaging plasmid 
containing gag, pol, rev and tat genes and panel c shows the envelope plasmid. LTR, long terminal 
repeat. PBS, tRNA primer binding site. RRE, rev response elements. VSV-G env, envelope 
pseudotyped with the G glycoprotein of vesicular stomatitis virus. cPPT, central polypurine tract. 
WPRE, woodchuck hepatitis virus post-transcriptional regulatory element.
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Supplementary Figure S4. Validation of the RNA-Seq data using qRT-PCR
RNA extracted from Control-KCs (Cont) and KID-KCs (KID) with or without treated S7 treatment 
were subjected to qRT-PCR using primers specific to the top 5 upregulated and 5 downregulated 
genes from the RNA-Seq analysis. The expression levels were calibrated by the internal control 
GAPDH gene. Data are represented as mean ± SEM and analyzed statistically using Student’s t-
test (n = 3). 
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Frozen tissue sections (6 μm) or paraformaldehyde-fixed cultured cells were incubated in PBS 
containing 3% fetal bovine serum and 0.3% Triton X-100 for 20 min at room temperature, and then 
incubated overnight at 4°C with a monoclonal Cx26 antibody (1:50; Thermo Fisher Scientific; Cat. 
#13-8100). Following several rinses with PBS, samples were incubated with a biotinylated 
secondary antibody (1:100; Vector Laboratories, Peterborough, UK) for 1 hr prior to visualization 
using an Alexa-Fluor 488- or 568-conjugated streptavidin (1:500; Invitrogen, Paisley, UK). 
Samples were counterstained with 5 µg/ml 4,6-diamino-2-phenylindole (DAPI, Vector 
Laboratories, Peterborough, UK), mounted using 10% Mowiol (Calbiochem, Nottingham, UK), 
and imaged using a Zeiss LSM 510 laser confocal microscope (Zeiss, Oberkochen, Germany). 
Images were recorded under the same settings (laser power, digital offset and gain) from three to 
seven continuous, non-overlapping fields on each slide, and analyzed using ImageJ v1.51n (NIH, 
Bethesda, MD, USA). 
siRNAs
Nineteen candidate AS-siRNAs (S1−S19) were designed and synthesized (Sigma, Dorset, UK). In 
siRNA screening experiments, the Silencer™ siRNA against GFP (Thermo Fisher Scientific, 
Paisley, UK) was used as a positive control (i.e. indicator of transfection and knockdown efficiency) 
and the siRNA against human HAS2 was used as a negative control (si-cont, Sigma, Dorset, UK). 
The sequences of si-cont are: sense 5’-AUAUCGUCAUGGUCUUCAU[dT][dT]-3’, and antisense 
5’-AUGAAGACCAUGACGAUAU [dT][dT]-3’.  
Page 48 of 109
2
Screening of AS-siRNAs
A fluorescence-based screening system was generated using HeLa cells stably expressing ectopic 
GJB2-WT or GJB2-c.148G>A which was fused to GFP cDNA at the 3’-terminus, driven by the 
cytomegalovirus promoter (CMV) (Supplementary Figure S4). We used the HIV-1 derived, self-
inactivating lentiviral vector pLNT-SFFV-MCS, with the WT or mutant CMV-GJB2-GFP cDNA 
sequence subcloned in. Lentiviruses were packaged by co-transfecting HEK-293T cells with the 
WT or mutant lentiviral vector, together with a plasmid encoding the vesicular stomatitis virus 
envelope and a packaging plasmid pCMV8.74 coding for lentiviral gag, pol and accessory proteins, 
tat and rev. Infectious viruses were harvested 72 hrs post-transfection, filtered through a 0.45-μm 
pore cellulose acetate filter, and then ultra-centrifuged at 23,000 × g for 2 hrs. Concentrated viruses 
were resuspended in the Opti-MEM® medium and the lentivirus stocks were kept at -80°C until 
use. The viral titres assessed by GFP expression using flow cytometry were 8.8×107 infectious unit 
(IU)/ml for WT viruses and 4.9×106 IU/ml for mutant viruses. HeLa cells were transduced with 
either WT or mutant lentiviruses and, upon confluence being reached, fluorescence-activated cell 
sorting was carried out to obtain single GFP+ cells using a Moflo XDP flow cytometer (Beckman 
Coulter, Luton, UK). These single cells were cultured until clonal expansion was observed. 
GFP+ clonal HeLa cells were seeded in a 24-well plate and, upon reaching a 70% confluence, were 
transiently transfected with each AS-siRNA at a concentration of 50 nM, using Lipofectamine™ 
RNAiMAX (Thermo Fisher Scientific, Paisley, UK). 24 hrs post-transfection, the level of GJB2-
GFP expression was assessed using flow cytometry (FACSCalibur™, BD Biosciences, Oxon, UK). 
Briefly, a non-fixed cell suspension was prepared in PBS containing 2% fetal bovine serum. 10,000 
cells from each sample were acquired using the FL1 channel with a 530-nm emission filter. Data 
were analyzed using the FlowJo software v10 (Tree Star Inc., Oregon, USA) and knockdown 
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efficiency was indicated by the decrease of mean GFP intensity (I) in transfected cells, calculated 
as: [1- (I allele-specific siRNA / I control siRNA)] × 100%.
Quantitative reverse transcriptase-PCR (qRT-PCR)
Total RNA was extracted from cells using TRIzol® reagent (Thermo Fisher Scientific, Paisley, UK). 
Complementary DNAs (cDNAs) were generated using the GeneAmp® RNA PCR Core Kit 
(Applied Biosystems, Warrington, UK). qRT-PCR was carried out using iTaq™ universal SYBR 
Green Supermix (Bio-Rad, Watford, UK). All primers used (including the c.148G>A allele-specific 
primers) are listed in Supplementary Table S1. The reactions were performed in triplicate on a 
C1000™ Thermal Cycler (Bio-Rad, Watford, UK) with conditions as follows: initial denaturation 
at 95°C for 1 min, followed by 39 thermocycles of 95°C for 15 s and 60°C for 30 s. Individual 
levels were normalized to GAPDH expression. qRT-PCR data were collected and analyzed using 
CFX-3.1 (Bio-Rad, Watford, UK) and relative expression of GJB2 was calculated using the 2-ΔΔCt 
method.
Immunoprecipitation and immunoblotting
Cells were cultured in a 100-mm dish to confluence, washed twice in PBS, and lysed using an 
immunoprecipitation (IP) lysis buffer containing 10 mM Tris-HCl (pH 7.4), 150 mM NaCl, 1% 
Triton X-100, 0.5% NP-40, 1 mM EDTA, 1 mM EGTA, 1 mM PMSF supplemented with protease 
inhibitor cocktail. The lysates were incubated on ice for 15 min with occasional vortexing, and then 
centrifuged at 12,000 × g at 4°C for 10 min. 1−1.5 mg protein from the supernatant was transferred 
to a fresh tube. 0.75 μg of a polyclonal Cx26 antibody (Thermo Fisher Scientific, Paisley, UK, Cat. 
#71-0500) was added to the lysate and incubated at 4°C for 2.5 hrs. Protein G-Sepharose beads (GE 
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Healthcare, Buckinghamshire, UK) of a 50% slurry was added to the lysate and mixed overnight at 
4°C. The beads were harvested by brief centrifugation and washed in IP lysis buffer without 
detergent. The final pellet was resuspended with a sample buffer containing 125 mM Tris-HCl (pH 
6.8), 5% β-mercaptoethanol, 4% sodium dodecyl sulfate (SDS), 10% glycerol and 0.0004% 
bromophenol blue, and boiled at 95°C for 10 min with brief vortexing to dissociate antigen-
antibody complexes from the beads. Samples were briefly centrifuged, and supernatants were 
analyzed immediately by immunoblotting (IB). The supernatant samples were separately by 
standard 12% SDS-PAGE in the NuPAGE™ MES SDS running buffer (Thermo Fisher Scientific, 
Paisley, UK). Membranes were blocked in 5% skimmed milk in PBS and then probed with a 
monoclonal Cx26 antibody at 1:1000 dilution (Merck Millipore, Watford, UK, Cat. #MABT198). 
An anti-mouse HRP-conjugated secondary antibody at 1:4000 dilution (GE Healthcare, 
Buckinghamshire, UK) was used. The target protein was detected using the ECL™ Prime Western 
Blotting Detection system (Amersham, Buckinghamshire UK). Densitometric analysis was 
performed on scanned images of blots.
Patch clamp for hemichannel activity
Whole-cell patch clamp was carried out at room temperature as previously described (Levit et al., 
2015). Cells were seeded onto 12-mm glass coverslips, which were later transferred to an 
experimental chamber filled with Tyrode’s bath solution containing (in mM): NaCl 137.7, KCl 5.4, 
NaOH 2.3, MgCl2 1, glucose 10, and HEPES 5 (pH 7.4). Patch pipettes were pulled from glass 
capillaries to a resistance of 3 6 MΩ with a horizontal puller (P-87, Sutter Instruments, Novato, ―
CA). Pipettes were filled with a solution containing (in mM): K-aspartate 120, HEPES 5, ethylene 
glycol tetraacetic acid 10, and NaATP 3 (pH 7.2). Solitary cells were measured for membrane 
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capacitance (Cm) and membrane currents (Im) invoked while the membrane potential was stepped 
from -110 mV to +110 mV in 20 mV increments. Voltage and current signals were recorded using 
an Axopatch-1D patch clamp amplifier coupled to a Digidata 1322A interface (Axon Instruments, 
Foster City, CA). Data were acquired and analyzed using Clampex 9.2 and Clampfit 10.2 software 
(Axon instruments), respectively. To control for variability in size of recorded cells, membrane 
current density (Im/Cm) was used as a direct measure of hemichannel activity. Comparison was 
made between current density at individual membrane voltages.
Neurobiotin uptake assay for hemichannel activity
The method was modified from a protocol described previously (Mese et al., 2011). Cells plated at 
a low density were gently washed twice with Ca2+, Mg2+-containing Hank's balanced salt solution 
(HBSS, Thermo Fisher Scientific, Paisley, UK), and then incubated in 0.1 mg/ml neurobiotin 
(Vector Laboratories, Peterborough, UK), a non-fluorescent tracer, in divalent-free HBSS at 37°C 
for 10 min to allow uptake of neurobiotin through open hemichannels. After two washes in Ca2+, 
Mg2+-containing HBSS, cells were fixed with 4% paraformaldehyde in PBS at 4°C, permeabilized 
with 0.3% Triton X-100 (Sigma, Dorset, UK) and then stained with Alexa Fluor 568-streptavidin 
conjugate at 1:400 dilution (Thermo Fisher Scientific, Paisley, UK) at room temperature. Labelled 
samples were imaged using an Olympus IX71 inverted fluorescence microscope (Olympus, Essex, 
UK) with the same exposure time applied to all samples. Five to ten neurobiotin uptake images 
from each group were recorded and analyzed using ImageJ v1.51n (NIH, Bethesda, MD, USA), 
and hemichannel activity was determined by the intensity of intracellular neurobiotin. 
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SLDT assay for gap junction intercellular communication
The scrape loading dye transfer assay (SLDT) was performed as described previously with minor 
modifications (Yum et al., 2007). Confluent monolayer cell cultures (24- or 48 hrs post-seeding) 
were gently rinsed twice with Ca2+, Mg2+-containing HBSS, and then replaced with divalent-free 
HBSS containing 0.1 mg/ml neurobiotin. Multiple parallel scrape lines were made on the cultures 
using a sharp scalpel blade, followed by incubation at 37°C for 10 min. Cells were washed twice 
with Ca2+, Mg2+-containing HBSS, fixed with 4% paraformaldehyde in PBS, and stained as 
described in the neurobiotin uptake assay section. Stained samples were imaged using an Olympus 
IX71 inverted fluorescence microscope. At least six scrape-wounded images and three background 
(non-scrape-wounded) images were recorded from each group. Images were analyzed using ImageJ 
v1.51n. GJ intercellular communication was determined by the extent of dye transfer, quantified by 
the total area between the scrape line and the point at which the fluorescence level reduced to 1.5 × 
the background fluorescence level.
Bio-engineered skin and human-murine chimeric skin graft model
The methods for preparing and grafting bioengineered skin in immunodeficient mice have been 
described previously (Di et al., 2011). In brief, immortalised KID-KCs at passage 7 were seeded on 
top of a fibrin matrix populated with live primary fibroblasts (passage 3) isolated from the KID 
syndrome patient. After keratinocytes reached confluence, the bio-engineered skin constructs were 
grafted onto the dorsum of 22-week-old NOD-severe combined immunodeficiency mice (NOD scid 
gamma [or NSG] mice, Charles River, UK). Three months post-grafting, mice were anesthetized 
and skin samples from graft area were taken post-mortem, embedded in paraffin and sectioned for 
histological examination.
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RNA sequencing (RNA-Seq) and data analysis
Cultured KID-KCs treated in triplicate with AS-siRNA were subject to RNA-Seq experiments 24 
hrs post-treatment and untreated cells were used as a control. RNA was extracted using TRIzol® 
reagent (Thermo Fisher Scientific, Paisley, UK) and RNA quality was measured using an Agilent 
Bioanalyser. All samples had an RNA integrity number greater than 9.8. cDNA libraries were 
prepared using the KAPA mRNA HyperPrep Kit (KAPA Biosystems) according to manufacturers' 
instructions. The libraries were sequenced with a 43-bp paired-end run using a NextSeq 500 
instrument (Illumina, San Diego, US). The sequence reads are available at GEO accession 
GSE131709.
Data were first demultiplexed and converted to fastq files using bcl2fastq Conversion (v2.19, 
Illumina). Fastq files were then pre-processed to remove adapter contamination and poor-quality 
base calls (Q20 or below) using a 5’ to 3’ sliding window approach. The remaining read data were 
mapped to the hg38 reference genome using the gapped aligner, RNA-STAR (v2.5b). Read data 
were counted per transcript by FeatureCounts (v1.4.6p5). Normalization, modelling and differential 
expression analysis were carried out using the SARTools package (v1.3.2, BioConductor). All 
reference genomes and annotation were obtained from the Illumina iGenomes repository. 
Differentially expressed genes were determined using a threshold of p-adj < 0.05 and |log2 fold 
change| ≥ 1 (Speranza et al., 2017).
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Supplementary Table S1. Primers 
Target Forward primers (5’-3’) Reverse primers (5’-3’)
Total GJB2 CTCCCGACGCAGAGCAAA GGTTGCCTCATCCCTCTCAT
GJB2 WT CTCCCGACGCAGAGCAAA GGCTGCAGGGTGTTGCAGACAATGTC
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Supplementary Table S2. List of 180 genes predicted to have seed sequence match with S7 
ABCA1 CRB2 IFT88 MED13L PLXNB1 SLC6A8
ABCC3 CREBBP IGF2R MED17 PPP4R1 SMCR7
ADAMTS7 CSPG4 IGSF9B MEGF8 PPRC1 SON
ADCK4 CTNNA1 INTS10 MST1R PRKCQ SPEN
ADCY1 CUL9 IQGAP3 MTF2 PRR14L STRBP
ADCY10 CYP2S1 KANSL2 MYO16 PRSS21 SVIL
ADH4 DAGLA KANSL3 NAT10 PRX SYNE2
AFP DMBT1 KAT5 NAV3 PSD3 SZT2
AGBL1 DSG2 KCNH4 NBEAL2 PTPRB TAF1
ANKRD28 DTNA KCNH5 NCOA1 RAB11FIP5 TAF5L
APOB DZANK1 KCNK16 NEURL4 REG1A TBCD
ARHGAP44 EDC4 KDR NLRC5 RINT1 TEK
ASH1L ERN1 KIAA0556 NLRP8 RNF17 TENM1
ATP13A1 ESPL1 KIAA1671 NOD1 RREB1 TENM4
BCAN FBXW2 KIAA1755 NOS2 RTTN TEP1
BIRC6 FCGBP KIDINS220 OCA2 RYR3 TLE2
BPIFB4 FLT1 KNTC1 OR51E1 SCN2A TLR8
C12orf55 FOCAD LAMA1 PCDH19 SCN3A TMPRSS4
C12orf63 FRAS1 LAP3 PCDHB13 SEC23A TRAK2
C16orf62 GALNT8 LIM2 PCDHB16 SEC31B TRIM60
C5 GJA10 LLGL2 PCDHGA6 SEMA4A TTC3
C6orf132 GNRHR LOC101929274 PCNXL3 SLC12A1 TUBGCP6
CACNA1B GPR112 LOC400499 PI4KA SLC26A6 UNC13A
CAND2 GPR137 LRP1B PIGV SLC30A5 URB1
CDS2 GRM3 LTBP4 PIWIL2 SLC35B1 UTRN
CNOT1 GRM8 LTN1 PKD1 SLC37A2 VPS13D
COL15A1 GSG2 LY75 PKHD1 SLC44A3 VWF
COL20A1 GTPBP2 LY75-CD302 PLCB3 SLC45A3 WNK2
COL4A2 HLCS MAGEL2 PLEKHG2 SLC4A4 WRN
COPA HLTF MAP7 PLEKHM2 SLC5A9 ZSWIM8
*Among the 180 genes, only GPR137 (underlined, bolded) was found in the top five up- or 
downregulated genes in KID-KCs treated by S7
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Supplementary Figure S1. AS-siRNAs: design and screening 
19 AS-siRNAs (with a 19-nt targeting sequence plus a deoxythymidine dinucleotide) were designed 
and designated GJB2 c.148G>A_S1−S19 (or S1−S19 in short form). WT and mutant GJB2 
sequences are shown and aligned with the siRNAs, with c.148G>A mutation underlined (a). 
Fluorescence-based screening results of the 19 AS-siRNAs in HeLa cells expressing WT or mutant 
GJB2-GFP fusion transgene are shown (b). The GFP siRNA (si-GFP) and the irrelevant siRNA (si-
cont) were used as positive and negative controls, respectively. The GJB2 knockdown efficiency 
of the AS-siRNAs was determined by the decrease in GFP intensity detected by flow cytometry (n 
= 3). The lead AS-siRNA, S7, inhibited the mutant GJB2 potently and specifically, but did not 
inhibit the WT GJB2. Data are normalized to the levels from cells treated with si-cont and shown 
as mean ± SEM.


















































Supplementary Figure S2. Validation of AS-siRNA screening suggested potent and mutation-
specific inhibitory activity of S7 
HeLa cells treated with 50 nM AS-siRNA (S7-S10), si-cont (cont), or si-GFP (GFP) were examined 
for Cx26-GFP protein expression using flow cytometry (a) and for total GJB2 mRNA using qRT-
PCR (b). Mutant-specific inhibition was achieved by S7 and S10 (a). These two siRNAs were 
further tested at mRNA level and non-specific inhibition of wildtype (WT) GJB2 was detected in 
cells treated with S10, but not in those treated with S7 (b). N.S, not significant; **p < 0.01; *p < 
0.001.
Page 59 of 109
1
Supplementary Figure S3. Schematic of the LNT-CMV-GJB2-GFP lentiviral vectors 
Panel a shows the self-inactivating, HIV-1-based vector with the transgene cloned in, which 
encodes the wildtype or c.148G>A mutant GJB2 cDNA fused to GFP reporter cDNA at the 3’ 
terminus driven by the cytomegalovirus promoter (CMV). Panel b shows the packaging plasmid 
containing gag, pol, rev and tat genes and panel c shows the envelope plasmid. LTR, long terminal 
repeat. PBS, tRNA primer binding site. RRE, rev response elements. VSV-G env, envelope 
pseudotyped with the G glycoprotein of vesicular stomatitis virus. cPPT, central polypurine tract. 
WPRE, woodchuck hepatitis virus post-transcriptional regulatory element.
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Supplementary Figure S4. Validation of the RNA-Seq data using qRT-PCR
RNA extracted from Control-KCs (Cont) and KID-KCs (KID) with or without treated S7 treatment 
were subjected to qRT-PCR using primers specific to the top 5 upregulated and 5 downregulated 
genes from the RNA-Seq analysis. The expression levels were calibrated by the internal control 
GAPDH gene. Data are represented as mean ± SEM and analyzed statistically using Student’s t-
test (n = 3). 
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Allele-specific siRNA for KID syndrome
Abbreviations:
KID: Keratitis-ichthyosis-deafness 
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KID-KC: KID syndrome patient-derived keratinocytes 
control-KC: Healthy donor-derived keratinocytes 
AS-siRNA: Allele-specific small interference RNA
SLDT: Scrape-loading dye transfer 
RNA-Seq: RNA sequencing
GESS: Genome-wide enrichment of seed sequences
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ABSTRACT
Keratitis-ichthyosis-deafness (KID) syndrome is a severe, untreatable condition characterized by 
ocular, auditory and cutaneous abnormalities, with major complications of infection and skin 
cancer. 86% of cases are caused by a heterozygous missense mutation (c.148G>A, p.D50N) in the 
GJB2 gene, encoding gap junction protein connexin 26 (Cx26), which alters gating properties of 
Cx26 channels in a dominant manner. We hypothesized that a mutant-allele-specific siRNA (AS-
siRNA) could rescue the cellular phenotype in patient keratinocytes. A KID syndrome cell line 
(KID-KC) was established from primary patient keratinocytes with a heterozygous p.D50N 
mutation. This displayed impaired gap junction communication and hyperactive hemichannels, 
confirmed by dye transfer, patch clamp and neurobiotin uptake assays. A human-murine chimeric 
skin graft model constructed with KID-KC mimicked patient skin in vivo, further confirming the 
validity of these cells as a model. In vitro treatment with AS-siRNA led to robust inhibition of the 
mutant GJB2 allele without altering expression of the wildtype. This corrected both gap junction 
and hemichannel activity. Notably, AS-siRNA treatment caused only low-level off-target effects 
in KID-KC, as detected by genome-wide RNA sequencing. Our data provide an important proof-
of-concept and model system for the potential use of AS-siRNA in treating KID syndrome, and 
other dominant genetic conditions.
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INTRODUCTION 
Keratitis-Ichthyosis-Deafness syndrome (KID syndrome, [MIM 148210]) is a rare, autosomal-
dominant condition characterized by ocular and auditory impairment and hyperkeratotic skin 
lesions (Burns, 1915). Ocular involvement includes photophobia and neovascularization, 
progressively reducing visual acuity (Caceres-Rios et al., 1996), and auditory impairment features 
sensorineural hearing loss (Patel et al., 2015). Skin involvement consists of erythrokeratodermic 
or verrucous plaques, and palmoplantar keratoderma with alopecia and/or onychodystrophy 
(Caceres-Rios et al., 1996, Coggshall et al., 2013). Moreover, KID syndrome is frequently 
complicated with chronic, opportunistic cutaneous infection, resulting in failure to thrive and, in 
severe cases, septicemia (Coggshall et al., 2013). Patients are at increased risk of developing skin 
malignancies, particularly squamous cell carcinoma (Coggshall et al., 2013). These complications 
can have a significant impact on life expectancy. Current cutaneous treatment is limited to 
symptomatic management, including retinoids to attempt to improve the skin barrier, antifungal 
and antibacterial agents for infection control (Coggshall et al., 2013). There is an unmet need for 
targeted treatment of this condition. 
The cause of KID syndrome was identified as heterozygous missense mutations in the GJB2 gene 
(van Steensel et al., 2002, Richard et al., 2002), which encodes a transmembrane, gap junction (GJ) 
channel-forming protein, connexin 26 (Cx26). GJs are clustered intercellular structures found in 
virtually all contacting cell types, enabling direct cell-cell communication via the exchange of ions, 
nutrients and signaling molecules with a molecular weight < 1 kDa (Levit et al., 2015, Elfgang et 
al., 1995). Connexin proteins, the constituents of GJs, can oligomerize to form hexameric structure 
known as connexons. On the plasma membrane, connexons can either function alone as 
hemichannels, or ‘dock’ with a compatible connexon from the adjacent cell membrane to form a 
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GJ (Laird, 2006). Undocked hemichannels serve as a conduit between the cytoplasm and the 
extracellular space of the cell, while GJs couple the cytoplasm of adjacent cells electrically and 
biochemically (Garcia et al., 2016). 
To date, twelve missense GJB2 mutations have been reported in KID syndrome, among which the 
mutation c.148G>A, resulting in the substitution of aspartic acid for asparagine at codon 50 
(p.D50N), is by far the most common mutation, accounting for 86% of cases in the largest 
European cohort (Mazereeuw-Hautier et al., 2007). At least 10 out of the 12 identified mutations, 
including p.D50N, have been associated with aberrant hemichannel behavior (Lee et al., 2009, 
Garcia et al., 2016, Donnelly et al., 2012, Mese et al., 2011), presented as elevated membrane 
currents (Lee et al., 2009), enhanced permeability to small-molecule tracers (Mese et al., 2011), 
and/or enhanced ATP release in response to a specific stimuli (Garcia et al., 2016, Donnelly et al., 
2012). Therefore, hemichannels have been considered a potential therapeutic target when 
developing new KID syndrome treatment (Levit et al., 2015, Xu et al., 2017). Recent work has 
shown that mefloquine, an FDA-approved anti-malarial drug, potently suppresses aberrant 
hemichannels in primary keratinocytes from a transgenic mouse model with heterozygous p.G45E 
mutation in GJB2 (Levit et al., 2015). Very recently, the monoclonal antibody abEC1.1 was 
developed, which specifically suppressed hemichannels formed by Cx26-wildtype (WT), p.G45E 
or p.D50N mutants (Xu et al., 2017). However, it is unclear whether those strategies can 
discriminate mutant GJB2 allele from the WT. This concern is particularly important given the 
context that most KID syndrome mutants exert dominant effects on co-expressed WT connexins 
(Di et al., 2005, Garcia et al., 2015). In the last decade, allele-specific small interference RNA (AS-
siRNA) technology has shown strong therapeutic potential in treatment of dominant genetic 
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disorders and brought clinical benefits to a patient with pachyonychia congenita (Trochet et al., 
2015). 
We present a specific and effective AS-siRNA against the GJB2 c.148G>A (p.D50N) mutation, 
which successfully rescues the abnormal cellular phenotype in patient-derived keratinocytes. Our 
approach could potentially be a novel future therapy for this debilitating and life-limiting condition. 
RESULTS
Patient-derived keratinocytes with heterozygous c.148G>A (p.D50N) mutation had aberrant 
gap junction and hemichannel behavior and caused hyperkeratotic skin morphology
Previous studies on mutant GJB2 expression, distribution and function have largely relied on 
ectopic expression of homozygous GJB2 mutations in Xenopus oocytes (Lopez et al., 2013) and 
HeLa cells (Press et al., 2017b). These models, however, do not accurately represent the genetic 
state in KID syndrome patients who are heterozygotes for GJB2 mutations, and therefore have 
limitations when used in preclinical evaluation for new therapeutic strategies. To overcome this, 
primary keratinocytes isolated from a fresh skin biopsy of the KID syndrome patient heterozygous 
for c.148G>A (p.D50N) mutation in GJB2 were immortalized using the lentiviral vector encoding 
HPV type 16 E6/E7 cDNA. 
The mutation GJB2 c.148G>A was confirmed in the immortalized cells (KID-KCs) (Figure 1a). 
Keratinocytes obtained from a healthy donor and immortalized with the same protocol were used 
as a control (control-KCs). Both immortalized cell lines showed polygonal morphology with 
various sizes in early passages but were more uniformly shaped in later passages (Figure 1b). The 
cell morphology and genotype were monitored over a propagation period up to 45 passages. There 
was no apparent change in morphology and the mutation in KID-KCs was expressed stably. The 
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expression of endogenous GJB2 mRNA in KID-KCs and control-KCs was examined by 
quantitative reverse transcriptase-PCR (qRT-PCR) using specific primers for total GJB2. A 
reduction of 44% in total GJB2 mRNA in KID-KCs was seen compared to that in control-KCs (n 
= 4, p = 0.24) (Figure 1c). The PCR amplicon of KID-KCs was sequenced, and the chromatogram 
exhibited a 1:1 ratio for WT : mutant allele peaks at c.148 locus (Figure 1a), suggesting similar 
mRNA expression levels for both WT and mutant alleles in KID-KCs. 
The expression of the Cx26 protein was also examined by immunoblotting. Several anti-Cx26 
antibodies have been used in immunoblotting previously (Yum et al., 2007, Press et al., 2017a), 
but the majority was used to detect Cx26 in rodent cells or tissues or in HeLa cells ectopically 
expressing Cx26, and only few were able to detect endogenous Cx26 in cultured human 
keratinocytes. This is possibly due to low endogenous Cx26 level or a lack of anti-Cx26 antibodies 
with sufficient affinity/specificity. We tested six antibodies and found that the pair of a rabbit 
polyclonal antibody (Thermo Fisher Scientific, 13-8100) and a mouse monoclonal antibody 
(Merck Millipore, MABT198) gave a clear band at 26 kDa when used for immunoprecipitation 
experiments (Figure 1d). Immunoprecipitation using these pair of antibodies showed a reduction 
in Cx26 protein expression in KID-KCs compared to control-KCs, which was consistent with the 
qRT-PCR results. 
The distribution of Cx26 in the cells was determined using immunostaining. In control-KCs, 
punctate or plaque-like Cx26 staining was observed at cell-cell contact sites (Figure 1e), which 
were indicated by membranous staining of E-cadherin, suggesting that WT Cx26 was able to traffic 
to the plasma membrane and formed GJ plaques. By contrast, Cx26 in KID-KCs failed to 
accumulate at membrane regions but showed a primarily discrete punctate staining pattern in the 
cytoplasm (Figure 1e). Although a small portion of GJ plaques overlaid with E-cadherin at the 
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plasma membrane, they were smaller in size compared to those observed in control-KCs. 
Interestingly, the immunostaining pattern of the patient skin did not show striking reduction or mis-
localization of Cx26 expression (Figure 1f). This could be, in part, explained by the in vitro culture 
condition which rendered keratinocytes more proliferative and less differentiative, given that Cx26 
is predominantly expressed in differentiated keratinocytes (Churko and Laird, 2013, Martin et al., 
2014).
The function of GJ intercellular communication in KID-KCs was assessed by scrape-loading dye 
transfer (SLDT) using the neurobiotin tracer and compared to control-KCs. Neurobiotin diffused 
extensively from initially scrape-loaded cells to neighboring cells in control-KCs (Figure 2a). In 
contrast, the diffusion of neurobiotin in KID-KCs reduced markedly and was almost confined to 
the first line of the scrape-wounded cells. Quantification of the images revealed a reduction of 58% 
in diffusion area in KID-KCs, compared to that in control-KCs (n = 3 each, p < 0.01), suggesting 
that the GJ channels formed in KID-KCs were defective (Figure 2b). 
Next, the activity of hemichannels in KID-KCs was measured using whole-cell patch clamp and 
neurobiotin uptake assay. Moderate membrane currents were recorded from control-KCs at both 
depolarizing and hyperpolarizing membrane voltages, whereas large currents were elicited from 
KID-KCs at all tested membrane voltages, more prominently at depolarizing voltages between +30 
mV and +110 mV (Figure 2c). The maximum current density recorded from KID-KCs was 80% 
greater than that in control-KCs (9.0 ± 1.3 pA/pF, n = 21 cells vs. 5.0 ± 0.6 pA/pF, n = 14 cells, 
measured at +110 mV, p < 0.05) (Figure 2d). Consistent with the patch clamp results, KID-KCs 
showed a marked increase in uptake of neurobiotin tracer compared to control-KCs (n = 29 and 34 
cells, respectively, p < 0.001) (Figure 2e). These results suggested enhanced membrane 
conductivity and neurobiotin permeability in KID-KCs, indicating hyperactive hemichannel 
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behavior conferred by the mutation. Our in vitro findings indicated that, despite expressing Cx26 
at a relatively low level in culture, the KID-KCs displayed an aberrant cellular phenotype that has 
been reported previously in other KID syndrome disease models (Arita et al., 2006, Lee et al., 2009, 
Garcia et al., 2016). 
To confirm that the immortalized KID-KCs remained capable of proliferation and differentiation, 
i.e. characteristics of primary keratinocytes in vivo, these cells were tested in a human-murine 
chimeric skin graft model (Di et al., 2011). Histological examination of the skin graft regenerated 
from immortalized KID-KCs showed similar features seen in the KID syndrome patient skin, 
including hyperkeratosis and spongiosis (Figure 3). Collectively, the immortalized KID-KCs are 
a suitable model for evaluating therapeutic efficacy of AS-siRNA for KID syndrome.
AS-siRNA selectively inhibited the c.148G>A mutation in KID-KCs
Nineteen candidate AS-siRNAs with a targeting sequence complementary to the c.148G>A 
mutation (S1−S19) were screened at a concentration of 50 nM in Hela cell lines stably expressing 
WT or mutant GJB2 fused with the GFP reporter gene. Both cell lines were transfected with each 
of 19 AS-siRNAs, followed by flow cytometry analysis for reduction of GFP intensity 
(Supplementary Figure S1b). The knockdown efficiency of S7 and S10 in cells expressing the 
mutant GJB2-GFP was approximately 50%. Since S7 inhibited mutant GJB2 specifically and 
reproducibly from three independent screening experiments (Supplementary Figure S2), this 
siRNA was selected for further study. 
The allele-specific action of S7 at 50 nM was tested in the KID-KCs harboring the heterozygous 
mutation. KID-KCs and control-KCs were treated with S7 and the mRNA expression of GJB2 in 
treated cells was examined 24 hrs post-treatment by qRT-PCR. The treatment resulted in a 
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significant decrease of 63% in total GJB2 mRNA in KID-KCs compared to untreated cells (n = 3, 
p = 0.0065), but the decrease was not detected in control-KCs with the same treatment (n = 3, p = 
0.84) (Figure 4a). Further investigation using allele-specific primers showed no difference in 
mRNA expression of the WT allele between untreated and S7-treated cells (n = 3, p = 0.51 for 
KID-KCs and p = 0.60 for control-KCs), whereas mRNA expression of the mutant allele in KID-
KCs was significantly inhibited by 43% following S7 treatment (n = 3, p = 0.0065). At protein 
level, Cx26 expression showed an average decrease of 56% (range 52−64%, n = 3) in total 
endogenous Cx26 expression in KID-KCs following S7 treatment, compared to those treated with 
an irrelevant siRNA, si-cont (Figure 4b-c). This change was not detected in S7-treated control-
KCs, which showed a slight increase in Cx26 expression (range 5−16%, n = 3). All these results 
indicated that S7 had strong selectivity for the mutant GJB2 c.148G>A allele over the WT allele 
in the patient keratinocytes, and it had little effect on the normal keratinocytes where only the WT 
allele was present.  
AS-siRNA treatment reversed aberrant gap junction and hemichannel functions in KID-KCs
KID-KCs treated with S7 or si-cont at 50 nM were further analyzed for GJ intercellular 
communication and hemichannel activity. GJ-mediated intercellular diffusion of neurobiotin tracer 
was analyzed 24 hrs post-treatment using the SLDT assay. The results showed a 24% increase in 
neurobiotin diffusion in KID-KCs treated with S7 compared to those treated with si-cont (n = 34 
and 37 images, respectively, p < 0.01) (Figure 5b, d), whereas no significant difference in 
neurobiotin transfer was observed in control-KCs treated with either S7 or si-cont (n = 30 and 35 
images, respectively, p > 0.05) (Figure 5a, c). The hemichannel activity in the treated cells was 
assessed by whole-cell patch clamp. The results showed a decrease of 35% in membrane current 
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density in KID-KCs treated with S7, compared to those treated with si-cont (9.02 ± 1.16 pA/pF, n 
= 20 cells vs. 5.86 ± 0.43 pA/pF, n = 22 cells, measured at +110 mV, p < 0.05), while no statistical 
differences were found in control-KCs following S7 or si-cont treatment (n =10 cells each group, 
p > 0.05) (Figure 5f-h). Notably, the current density level in S7-treated KID-KCs was comparable 
to that in control-KCs. The activity of hemichannels was further examined by neurobiotin uptake 
assay, which showed a significant decrease in neurobiotin uptake in KID-KCs after S7 treatment 
(n = 21 and 27 images, p < 0.001), in line with the patch clamp results (Figure 5i-j). 
These findings suggested functional recovery following the inhibition of mutant GJB2 allele by 
S7, namely improvement of the defective GJ-mediated cell coupling and reversal of the aberrant 
non-junctional hemichannel behavior, including electrical conduction and permeability. 
Low-level off-target effects of AS-siRNA, S7
Despite promising efficacy data obtained from S7, a general concern in preclinical AS-siRNA 
studies is off-target effects that may cause unintended alteration in unrelated gene expression 
(Trochet et al., 2018). To explore comprehensively the specificity of S7, RNA-Seq was carried out 
S7-treated or non-treated KID-KCs. 26485 genes from the libraries were mapped to the reference 
human genome (with 15,802 null- or low-expressed genes), among which only 6 genes were found 
to be differentially expressed in S7-treated KID-KCs compared to the non-treated cells (range of 
fold change: 2.01−2.32), indicating that S7 resulted in mild global effects on the KID-KC 
transcriptome. To validate the results, the top 5 upregulated (MMP1, MMP10, MMP9, ANGPTL4, 
CXCL5) and downregulated genes (GLB1L2, NSA2, AFAP1L1, GPR137, TMEM109) were further 
analyzed by qRT-PCR (Table 1). Control-KCs with or without S7 treatment were run in parallel 
as additional controls. The results confirmed the upregulation of the MMPs and the downregulation 
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of GPR137 in KID-KCs with comparable levels of fold change (Supplementary Figure S4); 
however, the MMPs were also found upregulated in S7-treated control-KCs. 
A common cause of siRNA-mediated gene alteration is sequence matching between the seed region 
of siRNA and the target mRNA (Yilmazel et al., 2014, Jackson and Linsley, 2010). To investigate 
whether this was an underlying mechanism for the differential expression of the above genes, we 
employed the online tool, genome-wide enrichment of seed sequences (GESS), to analyze the 
sequence of S7. A total of 180 genes were found to have sequence match(es) with S7 
(Supplementary Table S2), among which only GPR137 was found, with its 3’-untranslated region 
and coding sequence complementary to the seed region of either of the S7 strands. This implied 
that downregulation of GPR137 may have resulted from seed region-dependent off-target effects. 
The mechanism of alteration of the other genes remains to be clarified.
DISCUSSION 
We study AS-siRNA using KID-KC, an immortalized, patient-derived keratinocyte cell line which 
harbors a heterozygous c.148G>A mutation, representing the genetic state in KID syndrome 
patients. Although use of primary keratinocytes from patient skin biopsy would have been ideal 
for this study, these cells have a limited lifespan which restricts us from performing multiple 
experiments. To bypass the restrictions, we used immortalized patient keratinocytes due to their 
indefinite lifespan and capability of proliferation and differentiation, i.e. features of primary 
keratinocytes (Choi et al., 2017). This was further confirmed in our in vivo skin graft experiments, 
where regenerated skin grafts from immortalized KID-KCs recapitulated the epidermal 
architecture of the KID syndrome patient skin.
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Our immunostaining found lower Cx26 expression level in cultured immortalized cells compared 
to that in skin tissues. This is not surprising, as monolayer culture contains a dominating proportion 
of proliferating keratinocytes with low-level Cx26 expression (Martin et al., 2014). Despite the 
lower expression, we were able to show aberrant hemichannel and GJ behavior in KID-KCs, which 
is in line with data generated from previous in vitro models such as Xenopus oocytes (Lee et al., 
2009, Sanchez et al., 2013), HeLa cells (Di et al., 2005) and corneal epithelial cells (Shurman et 
al., 2005) ectopically expressing the c.148G>A mutant. This suggested that the reduced Cx26 
expression in vitro is unlikely to influence the interpretation of our results. Collectively, the 
immortalized, patient-derived model, which recapitulates the genetics, cellular and histological 
phenotypes of the condition, has significant advantages over the previous models and hence can 
serve as a good preclinical model for translational development of new therapeutic approaches.
The action of previously reported approaches to inhibit connexins, including monoclonal 
antibodies (Xu et al., 2017) and synthetic peptide mimetics (Becker et al., 2012), is mediated by 
either altering the biophysical property of target connexin channels or modulating interaction 
between target connexins and their binding partners. In contrast to those approaches, AS-siRNA 
silences target gene expression by degrading mRNA based on perfect sequence matching, thereby 
blocking the translation of target protein (Jackson and Linsley, 2010). As AS-siRNA is able to 
discriminate mutant and WT mRNA sequences differing by even a single base, we harness this 
technology to develop a targeted therapy for KID syndrome. Our results have confirmed that the 
lead AS-siRNA, S7, targeted to the mutant GJB2 allele in a potent and specific manner while 
maintaining expression of the WT allele and its protein function, providing strong basis for future 
translation of the AS-siRNA. 
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In human keratinocytes, Cx26 forms heteromeric and heterotypic channels with other compatible 
types of connexins (Di et al., 2001). These heterogenous channels have biophysical properties 
differing from their homogenous counterparts, providing dynamic regulation in response to 
different stimuli. Recent studies proposed that aberrant interaction with Cx43 is an emerging 
mechanism by which certain Cx26 mutants can cause diseases through heteromeric channels 
(Garcia et al., 2015, Shuja et al., 2016). We performed double immunofluorescence staining in our 
patient skin tissues and cultured KID-KCs, and the results did not show clear colocalization 
between Cx26 and Cx43 (data not shown). As this is our preliminary data, further investigation is 
required in the future. 
The low endogenous expression of Cx26 in human keratinocytes (Richard et al., 2002, Di et al., 
2001) posted a challenge in our initial attempts of immunoblotting to detect Cx26, which showed 
multiple bands. Issues regarding the presence of multiple bands were also reported by others 
(Gassmann et al., 2009), and were considered to result from oligomers and protein aggregates of 
Cx26. Our optimized immunoprecipitation/immunoblotting approach allowed enrichment of low-
abundant Cx26 in cultured patient keratinocytes, leading to successful quantification of siRNA-
medicated Cx26 knockdown. 
Our work provides proof-of-concept for the use of AS-siRNA in targeted therapy for KID 
syndrome. In the context of patient skin, the AS-siRNA-mediated reversal of connexin channel 
function may possibly improve the disturbed epidermal Ca2+ gradient that is contributed by 
homomeric or heteromeric channels formed by mutant Cx26 (Bosen et al., 2015), thereby leading 
to improved hyperkeratotic phenotype. Also, since enhanced hemichannel activity has been linked 
to release of inflammatory cytokines when exposing c.148G>A-expressing keratinocytes to 
peptidoglycans from an opportunistic pathogen, Staphylococcus aureus (Donnelly et al., 2012), 
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AS-siRNA is also likely to contribute towards control of skin infection and inflammation. 
Furthermore, the c.148G>A mutation has been found in the majority of KID syndrome patients. 
Thus, the mutation-targeted AS-siRNA would serve as potentially effective and safe therapeutic 
intervention for KID syndrome, the debilitating condition that has no effective specific treatment 
options at present. Although in vivo delivery of siRNA remains challenging, strategies including 
nanoparticles (Zheng et al., 2012), penetration enhancers (Hegde et al., 2014), microneedles 
(Chong et al., 2013) and electroporation (Broderick et al., 2012) have shown promise in topical 
siRNA delivery into the skin in a non- or minimally-invasive manner, causing silencing of target 
genes. We are currently optimizing a topical delivery platform and the therapeutic efficacy of the 
AS-siRNA will be tested in our in vivo human-murine chimeric skin graft model generated using 
immortalized KID-KCs. If successful, our strategy could potentially be adapted to other skin 
conditions with dominant mutations. 
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MATERIALS AND METHODS 
KID syndrome patient-derived keratinocytes 
3-mm punch biopsies from a KID syndrome patient with the heterozygous c.148G>A mutation, 
and a healthy volunteer donor, were obtained under a protocol approved by the local ethics 
committee (12/LO/1522) with informed written consent. The epidermis was isolated freshly from 
the biopsies as described previously (Di et al., 2011). The primary keratinocytes were immortalized 
by transduction with a second-generation, replication-deficient, self-inactivating HIV-1 lentiviral 
vector (Yanez-Munoz et al., 2006) constructed with human papilloma virus type 16 E6/E7 cDNA 
(Supplementary Figure S3). Immortalized cells were established following serial propagation and 
thereafter were cultured in the keratinocyte culture medium without feeder cells. 
Statistical analysis
All data were expressed as the mean ± standard error of the mean (SEM). Comparisons of data 
from qRT-PCR, patch clamp, neurobiotin uptake and SLDT experiments were made by Student’s 
t-test using GraphPad Prism v6.01 (GraphPad Software, San Diego, CA, USA). Differences with 
a p-value less than 0.05 were considered statistically significant. *p < 0.05; **p < 0.01; and ***p 
< 0.001.
Detailed methods for immunostaining, siRNA design, qRT-PCR, immunoprecipitation and 
immunoblotting, patch clamp, neurobiotin uptake, SLDT, RNA-Seq and in vivo skin graft 
experiments are described in Supplementary Materials.
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TABLES
Table 1. Top five up- and downregulated genes from the RNA-Seq experiments
Top five upregulated genes (KID-KCs, S7 vs. untreated)
Gene Protein Fold Change *p-adj
MMP1 Matrix metalloproteinase-1 2.24, up 9.50E-22
MMP10 Matrix metalloproteinase-10 2.06, up 4.19E-30
MMP9 Matrix metalloproteinase-9 1.95, up 4.90E-65
ANGPTL4 Angiopoietin-like 4 1.93, up 3.57E-28
CXCL5 C-X-C motif chemokine 5 1.74, up 6.26E-45
Top five downregulated genes (KID-KCs, S7 vs. untreated)
Gene Protein Fold Change *p-adj
GLB1L2 Galactosidase Beta 1 Like 2 2.31, down 2.17E-14
NSA2 Ribosome biogenesis homolog 2.16, down 1.99E-68
AFAP1L1 Actin filament-associated protein 1-like 1 2.01, down 1.99E-27
GPR137 G protein-coupled receptor 137 2.00, down 3.96E-09
TMEM109 Transmembrane Protein 109 1.94, down 3.92E-47
*p-adj, adjusted p-value for multiple statistical testing (Benjamini-Hochberg method) 
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FIGURE LEGENDS
Figure 1. Genotype, morphology, GJB2 expression and subcellular localization in 
keratinocytes 
cDNA sequences of GJB2 from the KID syndrome patient and healthy donor are shown in (a). The 
morphology of keratinocytes from healthy donor and KID patient at early passages (P1 or P5) and 
late passages (P35 or P45) is shown in (b). The mRNA expression of total GJB2, the wildtype 
(WT) allele and the mutant allele in healthy donor and KID patient keratinocytes determined by 
qRT-PCR are shown in (c). The total Cx26 protein (asterisk, at 26 kDa) expression was examined 
by immunoprecipitation and immunoblotting (d), which shows decreased Cx26 expression in 
patient cells. The expression of Cx26 detected by immunofluorescence staining is shown in (e), 
where gap junction plaques can be found at cell-cell junctions in normal keratinocyte (arrows), 
whereas Cx26 in KID patient keratinocytes was localized discretely in the cytoplasm (arrowheads). 
E-cadherin (E-Cad) was stained in green color. Cx26 expression in the skin is shown in (f), where 
punctate staining of Cx26 was observed (arrows). The dotted lines show dermal-epidermal junction. 
Bar = 100 μm (b) and 40 μm (e, f). KID: KID patient-derived keratinocytes; Cont: keratinocytes 
derived from the healthy donor; N.S: not significant; ***p < 0.001.
Figure 2. Abnormal gap junction and hemichannel behavior in KID-KCs
The gap junction intercellular communication in KID-KCs (KID) or control-KCs (Cont) was 
examined by the SLDT assay, and the hemichannel activity was examined by whole-cell patch 
clamp and neurobiotin uptake. Representative images of SLDT in the keratinocytes using 
neurobiotin tracer (red) is shown in (a). Data analysis (b) shows that KID-KCs had impaired ability 
to transfer neurobiotin to adjacent cells. Representative patch clamp records from single 
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keratinocytes in response to the voltage step protocol from -110 mV to +110 mV in 20 mV 
increments are shown in (c). The plot of current density against membrane voltage reveals 
aberrantly enhanced hemichannel activity in KID-KCs (d). Representative images of neurobiotin 
uptake (NB, red) are shown (e), with the nuclei stained with DAPI (blue). Data analysis shows 
increased uptake of NB in KID-KCs (f). All data are presented as the mean ± SEM. *p < 0.05; 
***p < 0.001. Bar = 200 μm. 
Figure 3. Epidermal morphology of grafted skin in human-murine chimeric skin graft model 
Primary fibroblasts and immortalized keratinocytes derived from the KID syndrome patient 
harboring heterozygous GJB2 c.148G>A mutation or a healthy donor were used to generate bio-
engineered skin sheets, which were grafted onto NOD-severe combined immunodeficiency mice 
(NSG mice). Eight weeks post-grafting, regenerated skin grafts were harvested. Macroscopic 
examination showed fine, dry scales in the graft generated from patient cells (d) compared to that 
generated from control cells (a). Histological examination showed hyperkeratosis and spongiosis 
in the patient skin graft (f), resembling that seen in the patient skin (c). The skin architecture of the 
control skin graft (e) was also similar to healthy donor skin (b). Bar = 100 µM.
Figure 4. Allele-specific GJB2 knockdown by S7
The mRNA expression of total GJB2, wildtype (WT) and the mutant (MUT) GJB2 alleles in 
control-KCs (Control) and KID-KC (KID) treated with AS-siRNA S7 was examined by qRT-PCR 
and compared to untreated cells (UT) (a). Total Cx26 protein expression in S7-treated cells from 
three independent immunoprecipitation(IP)/immunoblotting(IB) experiments (b). The expression 
was quantified using densitometry (c). β-actin was used as a loading control and HeLa cells were 
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used as a negative control. A reduction in total Cx26 expression was detected in KID-KCs after S7 
treatment, but such a change was not detected in control-KCs. N.S, not significant; **p < 0.01
Figure 5. S7 treatment corrected abnormal gap junction and hemichannel functions in KID-
KCs 
SLDT was performed in siRNA-treated KID-KCs (KID) and control-KCs (Cont) to assess GJ 
activity (a, b). The analysis of neurobiotin transfer (red) is shown (c, d). Each dot in panels c and 
d represents the average neurobiotin transfer from a single image. Three independent experiments 
were carried out and at least ten images were analyzed from each experiment. Restoration of GJ 
activity was detected in KID-KCs following S7 treatment. Whole-cell patch clamp (e-h) and 
neurobiotin uptake (i, j) were carried out to examine hemichannel activity. Records of currents 
from single cells under the voltage step protocol (e) are shown (f, g). The plot of current density 
against membrane voltage shows correction of hyperactive hemichannels in KID-KCs after S7 
treatment (h). Representative neurobiotin (NB, red) uptake images are shown in (i). The nuclei 
were stained with DAPI (blue). Data analysis shows reversal of aberrantly enhanced NB uptake in 
KID-KCs (j). Data are presented as the mean ± SEM. N.S, not significant; *p < 0.05; **p < 0.01; 
***p < 0.001. Bar = 200 μm. 





Frozen tissue sections (6 μm) or paraformaldehyde-fixed cultured cells were incubated in PBS 
containing 3% fetal bovine serum and 0.3% Triton X-100 for 20 min at room temperature, and then 
incubated overnight at 4°C with a monoclonal Cx26 antibody (1:50; Thermo Fisher Scientific; Cat. 
#13-8100). Following several rinses with PBS, samples were incubated with a biotinylated 
secondary antibody (1:100; Vector Laboratories, Peterborough, UK) for 1 hr prior to visualization 
using an Alexa-Fluor 488- or 568-conjugated streptavidin (1:500; Invitrogen, Paisley, UK). 
Samples were counterstained with 5 µg/ml 4,6-diamino-2-phenylindole (DAPI, Vector 
Laboratories, Peterborough, UK), mounted using 10% Mowiol (Calbiochem, Nottingham, UK), 
and imaged using a Zeiss LSM 510 laser confocal microscope (Zeiss, Oberkochen, Germany). 
Images were recorded under the same settings (laser power, digital offset and gain) from three to 
seven continuous, non-overlapping fields on each slide, and analyzed using ImageJ v1.51n (NIH, 
Bethesda, MD, USA). 
siRNAs
Nineteen candidate AS-siRNAs (S1−S19) were designed and synthesized (Sigma, Dorset, UK). In 
siRNA screening experiments, the Silencer™ siRNA against GFP (Thermo Fisher Scientific, 
Paisley, UK) was used as a positive control (i.e. indicator of transfection and knockdown efficiency) 
and the siRNA against human HAS2 was used as a negative control (si-cont, Sigma, Dorset, UK). 
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The sequences of si-cont are: sense 5’-AUAUCGUCAUGGUCUUCAU[dT][dT]-3’, and antisense 
5’-AUGAAGACCAUGACGAUAU [dT][dT]-3’.  
Screening of AS-siRNAs
A fluorescence-based screening system was generated using HeLa cells stably expressing ectopic 
GJB2-WT or GJB2-c.148G>A which was fused to GFP cDNA at the 3’-terminus, driven by the 
cytomegalovirus promoter (CMV) (Supplementary Figure S4). We used the HIV-1 derived, self-
inactivating lentiviral vector pLNT-SFFV-MCS, with the WT or mutant CMV-GJB2-GFP cDNA 
sequence subcloned in. Lentiviruses were packaged by co-transfecting HEK-293T cells with the 
WT or mutant lentiviral vector, together with a plasmid encoding the vesicular stomatitis virus 
envelope and a packaging plasmid pCMV8.74 coding for lentiviral gag, pol and accessory proteins, 
tat and rev. Infectious viruses were harvested 72 hrs post-transfection, filtered through a 0.45-μm 
pore cellulose acetate filter, and then ultra-centrifuged at 23,000 × g for 2 hrs. Concentrated viruses 
were resuspended in the Opti-MEM® medium and the lentivirus stocks were kept at -80°C until 
use. The viral titres assessed by GFP expression using flow cytometry were 8.8×107 infectious unit 
(IU)/ml for WT viruses and 4.9×106 IU/ml for mutant viruses. HeLa cells were transduced with 
either WT or mutant lentiviruses and, upon confluence being reached, fluorescence-activated cell 
sorting was carried out to obtain single GFP+ cells using a Moflo XDP flow cytometer (Beckman 
Coulter, Luton, UK). These single cells were cultured until clonal expansion was observed. 
GFP+ clonal HeLa cells were seeded in a 24-well plate and, upon reaching a 70% confluence, were 
transiently transfected with each AS-siRNA at a concentration of 50 nM, using Lipofectamine™ 
RNAiMAX (Thermo Fisher Scientific, Paisley, UK). 24 hrs post-transfection, the level of GJB2-
GFP expression was assessed using flow cytometry (FACSCalibur™, BD Biosciences, Oxon, UK). 
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Briefly, a non-fixed cell suspension was prepared in PBS containing 2% fetal bovine serum. 10,000 
cells from each sample were acquired using the FL1 channel with a 530-nm emission filter. Data 
were analyzed using the FlowJo software v10 (Tree Star Inc., Oregon, USA) and knockdown 
efficiency was indicated by the decrease of mean GFP intensity (I) in transfected cells, calculated 
as: [1- (I allele-specific siRNA / I control siRNA)] × 100%.
Quantitative reverse transcriptase-PCR (qRT-PCR)
Total RNA was extracted from cells using TRIzol® reagent (Thermo Fisher Scientific, Paisley, UK). 
Complementary DNAs (cDNAs) were generated using the GeneAmp® RNA PCR Core Kit 
(Applied Biosystems, Warrington, UK). qRT-PCR was carried out using iTaq™ universal SYBR 
Green Supermix (Bio-Rad, Watford, UK). All primers used (including the c.148G>A allele-specific 
primers) are listed in Supplementary Table S1. The reactions were performed in triplicate on a 
C1000™ Thermal Cycler (Bio-Rad, Watford, UK) with conditions as follows: initial denaturation 
at 95°C for 1 min, followed by 39 thermocycles of 95°C for 15 s and 60°C for 30 s. Individual 
levels were normalized to GAPDH expression. qRT-PCR data were collected and analyzed using 
CFX-3.1 (Bio-Rad, Watford, UK) and relative expression of GJB2 was calculated using the 2-ΔΔCt 
method.
Immunoprecipitation and immunoblotting
Cells were cultured in a 100-mm dish to confluence, washed twice in PBS, and lysed using an 
immunoprecipitation (IP) lysis buffer containing 10 mM Tris-HCl (pH 7.4), 150 mM NaCl, 1% 
Triton X-100, 0.5% NP-40, 1 mM EDTA, 1 mM EGTA, 1 mM PMSF supplemented with protease 
inhibitor cocktail. The lysates were incubated on ice for 15 min with occasional vortexing, and then 
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centrifuged at 12,000 × g at 4°C for 10 min. 1−1.5 mg protein from the supernatant was transferred 
to a fresh tube. 0.75 μg of a polyclonal Cx26 antibody (Thermo Fisher Scientific, Paisley, UK, Cat. 
#71-0500) was added to the lysate and incubated at 4°C for 2.5 hrs. Protein G-Sepharose beads (GE 
Healthcare, Buckinghamshire, UK) of a 50% slurry was added to the lysate and mixed overnight at 
4°C. The beads were harvested by brief centrifugation and washed in IP lysis buffer without 
detergent. The final pellet was resuspended with a sample buffer containing 125 mM Tris-HCl (pH 
6.8), 5% β-mercaptoethanol, 4% sodium dodecyl sulfate (SDS), 10% glycerol and 0.0004% 
bromophenol blue, and boiled at 95°C for 10 min with brief vortexing to dissociate antigen-
antibody complexes from the beads. Samples were briefly centrifuged, and supernatants were 
analyzed immediately by immunoblotting (IB). The supernatant samples were separately by 
standard 12% SDS-PAGE in the NuPAGE™ MES SDS running buffer (Thermo Fisher Scientific, 
Paisley, UK). Membranes were blocked in 5% skimmed milk in PBS and then probed with a 
monoclonal Cx26 antibody at 1:1000 dilution (Merck Millipore, Watford, UK, Cat. #MABT198). 
An anti-mouse HRP-conjugated secondary antibody at 1:4000 dilution (GE Healthcare, 
Buckinghamshire, UK) was used. The target protein was detected using the ECL™ Prime Western 
Blotting Detection system (Amersham, Buckinghamshire UK). Densitometric analysis was 
performed on scanned images of blots.
Patch clamp for hemichannel activity
Whole-cell patch clamp was carried out at room temperature as previously described (Levit et al., 
2015). Cells were seeded onto 12-mm glass coverslips, which were later transferred to an 
experimental chamber filled with Tyrode’s bath solution containing (in mM): NaCl 137.7, KCl 5.4, 
NaOH 2.3, MgCl2 1, glucose 10, and HEPES 5 (pH 7.4). Patch pipettes were pulled from glass 
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capillaries to a resistance of 3 6 MΩ with a horizontal puller (P-87, Sutter Instruments, Novato, ―
CA). Pipettes were filled with a solution containing (in mM): K-aspartate 120, HEPES 5, ethylene 
glycol tetraacetic acid 10, and NaATP 3 (pH 7.2). Solitary cells were measured for membrane 
capacitance (Cm) and membrane currents (Im) invoked while the membrane potential was stepped 
from -110 mV to +110 mV in 20 mV increments. Voltage and current signals were recorded using 
an Axopatch-1D patch clamp amplifier coupled to a Digidata 1322A interface (Axon Instruments, 
Foster City, CA). Data were acquired and analyzed using Clampex 9.2 and Clampfit 10.2 software 
(Axon instruments), respectively. To control for variability in size of recorded cells, membrane 
current density (Im/Cm) was used as a direct measure of hemichannel activity. Comparison was 
made between current density at individual membrane voltages.
Neurobiotin uptake assay for hemichannel activity
The method was modified from a protocol described previously (Mese et al., 2011). Cells plated at 
a low density were gently washed twice with Ca2+, Mg2+-containing Hank's balanced salt solution 
(HBSS, Thermo Fisher Scientific, Paisley, UK), and then incubated in 0.1 mg/ml neurobiotin 
(Vector Laboratories, Peterborough, UK), a non-fluorescent tracer, in divalent-free HBSS at 37°C 
for 10 min to allow uptake of neurobiotin through open hemichannels. After two washes in Ca2+, 
Mg2+-containing HBSS, cells were fixed with 4% paraformaldehyde in PBS at 4°C, permeabilized 
with 0.3% Triton X-100 (Sigma, Dorset, UK) and then stained with Alexa Fluor 568-streptavidin 
conjugate at 1:400 dilution (Thermo Fisher Scientific, Paisley, UK) at room temperature. Labelled 
samples were imaged using an Olympus IX71 inverted fluorescence microscope (Olympus, Essex, 
UK) with the same exposure time applied to all samples. Five to ten neurobiotin uptake images 
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from each group were recorded and analyzed using ImageJ v1.51n (NIH, Bethesda, MD, USA), 
and hemichannel activity was determined by the intensity of intracellular neurobiotin. 
 
SLDT assay for gap junction intercellular communication
The scrape loading dye transfer assay (SLDT) was performed as described previously with minor 
modifications (Yum et al., 2007). Confluent monolayer cell cultures (24- or 48 hrs post-seeding) 
were gently rinsed twice with Ca2+, Mg2+-containing HBSS, and then replaced with divalent-free 
HBSS containing 0.1 mg/ml neurobiotin. Multiple parallel scrape lines were made on the cultures 
using a sharp scalpel blade, followed by incubation at 37°C for 10 min. Cells were washed twice 
with Ca2+, Mg2+-containing HBSS, fixed with 4% paraformaldehyde in PBS, and stained as 
described in the neurobiotin uptake assay section. Stained samples were imaged using an Olympus 
IX71 inverted fluorescence microscope. At least six scrape-wounded images and three background 
(non-scrape-wounded) images were recorded from each group. Images were analyzed using ImageJ 
v1.51n. GJ intercellular communication was determined by the extent of dye transfer, quantified by 
the total area between the scrape line and the point at which the fluorescence level reduced to 1.5 × 
the background fluorescence level.
Bio-engineered skin and human-murine chimeric skin graft model
The methods for preparing and grafting bioengineered skin in immunodeficient mice have been 
described previously (Di et al., 2011). In brief, immortalized KID-KCs at passage 7 were seeded 
on top of a fibrin matrix populated with live primary fibroblasts (passage 3) isolated from the KID 
syndrome patient. After keratinocytes reached confluence, the bio-engineered skin constructs were 
grafted onto the dorsum of 22-week-old NOD-severe combined immunodeficiency mice (NOD scid 
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gamma [or NSG] mice, Charles River, UK). Three months post-grafting, mice were anesthetized 
and skin samples from graft area were taken post-mortem, embedded in paraffin and sectioned for 
histological examination.
RNA sequencing (RNA-Seq) and data analysis
Cultured KID-KCs treated in triplicate with AS-siRNA were subject to RNA-Seq experiments 24 
hrs post-treatment and untreated cells were used as a control. RNA was extracted using TRIzol® 
reagent (Thermo Fisher Scientific, Paisley, UK) and RNA quality was measured using an Agilent 
Bioanalyser. All samples had an RNA integrity number greater than 9.8. cDNA libraries were 
prepared using the KAPA mRNA HyperPrep Kit (KAPA Biosystems) according to manufacturers' 
instructions. The libraries were sequenced with a 43-bp paired-end run using a NextSeq 500 
instrument (Illumina, San Diego, US). The sequence reads are available at GEO accession 
GSE131709.
Data were first demultiplexed and converted to fastq files using bcl2fastq Conversion (v2.19, 
Illumina). Fastq files were then pre-processed to remove adapter contamination and poor-quality 
base calls (Q20 or below) using a 5’ to 3’ sliding window approach. The remaining read data were 
mapped to the hg38 reference genome using the gapped aligner, RNA-STAR (v2.5b). Read data 
were counted per transcript by FeatureCounts (v1.4.6p5). Normalization, modelling and differential 
expression analysis were carried out using the SARTools package (v1.3.2, BioConductor). All 
reference genomes and annotation were obtained from the Illumina iGenomes repository. 
Differentially expressed genes were determined using a threshold of p-adj < 0.05 and |log2 fold 
change| ≥ 1 (Speranza et al., 2017).
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Supplementary Tables
Supplementary Table S1. Primers 
Target Forward primers (5’-3’) Reverse primers (5’-3’)
Total GJB2 CTCCCGACGCAGAGCAAA GGTTGCCTCATCCCTCTCAT
GJB2 WT CTCCCGACGCAGAGCAAA GGCTGCAGGGTGTTGCAGACAATGTC
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Supplementary Table S2. List of 180 genes predicted to have seed sequence match with S7 
ABCA1 CRB2 IFT88 MED13L PLXNB1 SLC6A8
ABCC3 CREBBP IGF2R MED17 PPP4R1 SMCR7
ADAMTS7 CSPG4 IGSF9B MEGF8 PPRC1 SON
ADCK4 CTNNA1 INTS10 MST1R PRKCQ SPEN
ADCY1 CUL9 IQGAP3 MTF2 PRR14L STRBP
ADCY10 CYP2S1 KANSL2 MYO16 PRSS21 SVIL
ADH4 DAGLA KANSL3 NAT10 PRX SYNE2
AFP DMBT1 KAT5 NAV3 PSD3 SZT2
AGBL1 DSG2 KCNH4 NBEAL2 PTPRB TAF1
ANKRD28 DTNA KCNH5 NCOA1 RAB11FIP5 TAF5L
APOB DZANK1 KCNK16 NEURL4 REG1A TBCD
ARHGAP44 EDC4 KDR NLRC5 RINT1 TEK
ASH1L ERN1 KIAA0556 NLRP8 RNF17 TENM1
ATP13A1 ESPL1 KIAA1671 NOD1 RREB1 TENM4
BCAN FBXW2 KIAA1755 NOS2 RTTN TEP1
BIRC6 FCGBP KIDINS220 OCA2 RYR3 TLE2
BPIFB4 FLT1 KNTC1 OR51E1 SCN2A TLR8
C12orf55 FOCAD LAMA1 PCDH19 SCN3A TMPRSS4
C12orf63 FRAS1 LAP3 PCDHB13 SEC23A TRAK2
C16orf62 GALNT8 LIM2 PCDHB16 SEC31B TRIM60
C5 GJA10 LLGL2 PCDHGA6 SEMA4A TTC3
C6orf132 GNRHR LOC101929274 PCNXL3 SLC12A1 TUBGCP6
CACNA1B GPR112 LOC400499 PI4KA SLC26A6 UNC13A
CAND2 GPR137 LRP1B PIGV SLC30A5 URB1
CDS2 GRM3 LTBP4 PIWIL2 SLC35B1 UTRN
CNOT1 GRM8 LTN1 PKD1 SLC37A2 VPS13D
COL15A1 GSG2 LY75 PKHD1 SLC44A3 VWF
COL20A1 GTPBP2 LY75-CD302 PLCB3 SLC45A3 WNK2
COL4A2 HLCS MAGEL2 PLEKHG2 SLC4A4 WRN
COPA HLTF MAP7 PLEKHM2 SLC5A9 ZSWIM8
*Among the 180 genes, only GPR137 (underlined, bolded) was found in the top five up- or 
downregulated genes in KID-KCs treated by S7
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Supplementary Figures
Supplementary Figure S1. AS-siRNAs: design and screening 
19 AS-siRNAs (with a 19-nt targeting sequence plus a deoxythymidine dinucleotide) were designed 
and designated GJB2 c.148G>A_S1−S19 (or S1−S19 in short form). WT and mutant GJB2 
sequences are shown and aligned with the siRNAs, with c.148G>A mutation underlined (a). 
Fluorescence-based screening results of the 19 AS-siRNAs in HeLa cells expressing WT or mutant 
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GJB2-GFP fusion transgene are shown (b). The GFP siRNA (si-GFP) and the irrelevant siRNA (si-
cont) were used as positive and negative controls, respectively. The GJB2 knockdown efficiency 
of the AS-siRNAs was determined by the decrease in GFP intensity detected by flow cytometry (n 
= 3). The lead AS-siRNA, S7, inhibited the mutant GJB2 potently and specifically, but did not 
inhibit the WT GJB2. Data are normalized to the levels from cells treated with si-cont and shown 
as mean ± SEM.


















































Supplementary Figure S2. Validation of AS-siRNA screening suggested potent and mutation-
specific inhibitory activity of S7 
HeLa cells treated with 50 nM AS-siRNA (S7-S10), si-cont (cont), or si-GFP (GFP) were examined 
for Cx26-GFP protein expression using flow cytometry (a) and for total GJB2 mRNA using qRT-
PCR (b). Mutant-specific inhibition was achieved by S7 and S10 (a). These two siRNAs were 
further tested at mRNA level and non-specific inhibition of wildtype (WT) GJB2 was detected in 
cells treated with S10, but not in those treated with S7 (b). N.S, not significant; **p < 0.01; *p < 
0.001.
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Supplementary Figure S3. Schematic of the LNT-CMV-GJB2-GFP lentiviral vectors 
Panel a shows the self-inactivating, HIV-1-based vector with the transgene cloned in, which 
encodes the wildtype or c.148G>A mutant GJB2 cDNA fused to GFP reporter cDNA at the 3’ 
terminus driven by the cytomegalovirus promoter (CMV). Panel b shows the packaging plasmid 
containing gag, pol, rev and tat genes and panel c shows the envelope plasmid. LTR, long terminal 
repeat. PBS, tRNA primer binding site. RRE, rev response elements. VSV-G env, envelope 
pseudotyped with the G glycoprotein of vesicular stomatitis virus. cPPT, central polypurine tract. 
WPRE, woodchuck hepatitis virus post-transcriptional regulatory element.
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Supplementary Figure S4. Validation of the RNA-Seq data using qRT-PCR
RNA extracted from Control-KCs (Cont) and KID-KCs (KID) with or without treated S7 treatment 
were subjected to qRT-PCR using primers specific to the top 5 upregulated and 5 downregulated 
genes from the RNA-Seq analysis. The expression levels were calibrated by the internal control 
GAPDH gene. Data are represented as mean ± SEM and analyzed statistically using Student’s t-
test (n = 3). 
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